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Abstract
In many real-world scenarios, we need to use multi-class classifiers to properly identify all
classes in a dataset. To evaluate performance of multi-class classifiers, we need to take various
parameters into account. I created a framework that can be used to drill into the differences
between algorithms in specific scenarios and better compare multiple classifiers. This allows
researchers to better identify strengths and weaknesses of particular classifiers.
Single-cell RNA-seq allows cancer researchers to define complex cell types (i.e. classes)
in the tumour micro-environments (TME). Using eight datasets, I assessed performance of 26
methods from different perspectives, such as the ability to identify under-represented or imbalanced classes or identify distinct but related subgroups that have not been seen before within a
population. This study can be used to select the best methods for multi-class classifications of
complex datasets, such as scRNA-seq TME datasets, and provides avenues for future work.

Keywords: scRNA-seq, cancer, tumour micro-environment, supervised learning, unsupervised learning, machine learning, data science, information visualisation, multi-class classification
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Summary for Lay Audience

Supervised learning is the process of teaching an algorithm how to predict a result given a
set of observations. The simplest case is a binary classifier which can only choose between
two different results. Most real world problems, however, have more than two results, and
multi-class classifiers are better suited for these problems. Multi-class classifiers are able to
predict more than two results. Unfortunately, with many results it is hard to gauge how well a
classifier predicts the correct result or solves a problem. I have created a set of guidelines that
can be used to test these classifiers in a more complete manner, and better understand how they
perform relative to each other. This allows users to compare classifiers and choose the best
one that solves a particular problem, or identify shortcomings in a newly developed classifier
in order to improve how a problem is solved.
Tumour micro-environments (TME) contain a variety of cell types which can affect cancer
progression, making accurate identification of cell types important. Single-cell RNA sequencing (scRNA-seq) measures gene expression profiles of individual cells, yet analysis of scRNAseq data involves manual cell type identification, leading to potentially inaccurate predictions
and irreproducible results. Automated algorithms exist, but are mainly tested on normal tissues. To understand how they perform on TME, I evaluated 26 automated cell-type labelling
methods using 8 cancer datasets. I found that algorithms which learn from individual cells
within a sample perform better than those using cell clusters for prediction. Additionally, the
cell-based methods are better able to identify malignant cells in the TME, while cluster-based
algorithms have higher performance on non-malignant cell types than malignant ones. My
study provides guidelines for the selection of a cell type identification method.
ii
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Chapter 1
Introduction

1.1

Multi-class classification

Classification is the process of predicting which class an object or data point belongs to [42].
The simplest case is binary classification, where a classifier’s goal is to state whether an object
belongs in class A or class B. Many real-world problems, such as image recognition, optical
character recognition, parts of natural language processing and autonomous driving systems,
and tumour classification are better framed as multi-class classification problems since sorting
objects into one of two classes is insufficient. These problems are better solved by a multi-class
classifier, which can sort objects into more than two simple classes.
Due to the number of classes present in many multi-class problems, it can be difficult to
compare and benchmark groups of classifiers in order to find the top performers or identify
shortcomings in existing methods. As the number of classes increases, the number of ways
a classifier could make an error increases quadratically. In a binary classification problem, a
prediction is either right or wrong, but in a problem with four classes (i.e. A,B,C,D) an instance
1

2

Chapter 1. Introduction

could be class A, but predicted to be B, C, or D. That is three different ways for the classifier
to incorrectly predict the class for that one instance. Additionally, two classifiers could get the
same proportion of their predictions correct, but have completely different behaviour with respect to the incorrect predictions. The simpler metrics used with binary classification problems
often fail to capture this complexity in multi-class problems, and many of the existing metrics
can hide aspects of a classifier’s performance [39]. Commonly used comparisons could overlook nuances in a multi-class classifier’s performance, such as the ability to accurately identify
under-represented classes or perform adequately on varying class sizes between datasets. For
example, when classifying cell types a classifier may successfully identify one common cell
type but none of the more under-represented ones. In this case, accuracy would give the algorithm a good score for correctly identifying a large number of the individual cells despite
completely failing to identify some classes. Consider a different algorithm that identifies fewer
individual cells overall than the first algorithm, but is able to achieve passable performance in
all classes – even the under-represented ones. This algorithm may have a lower accuracy, but
is potentially more useful in a clinical setting where understanding the composition of a tissue
sample is important. In order to properly understand how multi-class classifiers perform and
develop new ones, a more robust benchmarking framework is needed.

1.2

RNA sequencing

Single-cell RNA sequencing (scRNA-seq) is a novel technology for measuring expression of
genes within individual cells. This enables the precise examination of cellular heterogeneity
and tissue composition within a given sample, something that is especially relevant in the

1.2. RNA sequencing

3

study of cancer [21, 85]. Current bulk RNA-seq methods can only capture the average gene
expression of all cells within a sample. While this can be useful for studying some healthy
tissues, cancerous tissues are more complex due to the many different mutations that may have
arisen leading to the cells becoming cancerous [3,4,48,52,59]. The tumour micro-environment
(TME) is comprised of various stromal, immune, cancer, and healthy cells, all of which must be
understood in order to properly diagnose and treat the disease. Interactions between these cell
types or behaviours exhibited by small sub-populations of cells within the TME can affect how
the disease progresses, responds to treatment, or metastasises. With scRNA-seq, researchers
are able to catalogue and identify each individual cell population within a tumour to give a
much more precise diagnosis.
This data does not come without problems, however. scRNA-seq data can contain tens of
thousands of cells, each with tens of thousands of genes expressed. The sheer volume of this
data makes it difficult to study, and more effective computational methods are needed. Current strategies usually involve clustering the cells in order to automatically separate them into
similar groups that can be studied as a whole. Clustering can easily reduce a set of thousands
of cells to a dozen or fewer clusters, a much more manageable number. Often the average
expression of a cluster is then analysed manually with differential gene analysis or fed through
a cluster labelling algorithm such as Gene Set Variation Analysis (GSVA) or scCATCH [26].
Manual analysis of these clusters can leave much to be desired, often relying on the use of certain marker gene sets (found via literature searches) to predict which cell type a cluster seems
to be through subjective study of differential expression. This approach is time consuming and
can result in inconsistencies between studies, leading to poor reproducibility. Automated cell
cluster labelling algorithms are much faster and more reproducible, but few have been tested
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on the TME. Furthermore, these methods are still based on analysis of marker gene sets and
are thus limited in their analysis of the clusters.
With the growth of machine learning, many classifiers which focus on individual cells
instead of only cell clusters have been proposed, but again, few have been tested on the TME
[1]. By examining individual cells instead of the smoothed, average expression within clusters,
these methods have more data available for use in their classification functions, and do not rely
on a separate clustering algorithm to correctly separate similar cell sub-populations. In order to
further improve the study of the TME through scRNA-seq, a comprehensive review of various
computational tools for identifying cell types within a sample is needed.

1.3

Contents of this thesis

The main contributions of this thesis are:
1. Development of a robust framework for benchmarking and comparing multi-class classification methods that fulfils the need for a standardised method of understanding the
performance of these classifiers.
2. A reference dataset aggregation framework, with an example presenting an R package
containing many TME scRNA-seq datasets for use in the creation and testing of machine
learning methods.
3. A comparison of existing automated scRNA-seq cell type classification methods on the
tumour micro-environment, using my proposed framework.
In this thesis, I will first discuss the relevant background information (Chapter 2). I then
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present a framework that can be used to understand and compare the performance of various
multi-class classification methods across multiple datasets in chapter 3. A key component
of this framework is the use of per-class performance metrics as features that unsupervised
learning methods can use to interpret patterns in the performance of many algorithms. This
framework improves the study of such classifiers – especially in feature-rich scenarios with
many datasets, classifiers, or classes present – making it easier for researchers to understand
how certain classifiers outperform others or find performance gaps in existing classifiers. In
addition to presenting the framework, I discuss how it can be used in the scRNA-seq case
study found later in my thesis as well as the hypothetical problem of classifying unknown
galaxies. Chapter 4 provides a data aggregation framework through the R package TMExplorer
which collects an assortment of TME scRNA-seq datasets for use in development and testing
of computational methods, thus reducing the effort required by researchers looking to develop
and use these methods. Chapter 5 contains a case study using both frameworks to first gather
a collection of high quality scRNA-seq data and then benchmark a set of classifiers in order to
provide recommendations for those looking to study their own scRNA-seq samples or improve
upon existing labelling techniques. Finally, the concluding chapter (6) reiterates my significant
contributions and discusses areas for future work related to this thesis.

Chapter 2
Background
In this chapter I will describe the machine learning and RNA-sequencing topics necessary to
understand later chapters in my thesis. I use machine learning methods to study data sourced
from RNA-sequencing.

2.1

Machine learning

In this section, I describe the machine learning techniques use throughout my thesis. Supervised learning is used to predict the cell types present in an RNA-seq sample, clustering is used
as a preliminary step for some other automated single cell RNA-sequencing pipelines, and the
performance metrics are used to benchmark the algorithms.

2.1.1

Supervised learning

Supervised learning is the process of learning to predict output labels given a set of inputs. To
learn a problem, a classifier is fed a set of inputs for which the classes are known, and these
6
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inputs are used to estimate the true function mapping inputs to outputs in the problem. Inputs
have features that provide some sort of information about them, and these features can be used
to separate some inputs from others. Outputs can be continuous in regression tasks – which
simply estimate a continuous function based on the inputs as in linear regression – and discrete
in classification tasks. For my thesis I will focus on the latter. Functions are approximated by
viewing data points in a sample as points within n-dimensional space, where n is the number of
features. There is some function f (x) that maps inputs to a class, and we want to find it. Since
it can be difficult to find the exact function, it is instead approximated. In the case of a linear
problem, we can use ordinary least squares (OLS, described more next paragraph) to create an
approximate f (x) = X T β where X is the matrix of data points and β is the set of parameters
used for approximation [42].
A classifier seeks to identify which class an input belongs to based on its features. Some
classifiers are as follows; Linear model classifiers predict the output class (Ŷ) using a linear
equation 2.1. In this model, the intercept of the equation represents bias, and the model coefficients are multiplied by the inputs. Ordinary least squares (OLS) is often used to fit such a
model. In OLS, coefficients are selected such that the residual sum of squares (RSS, equation
2.2) is minimised. This results in a continuous function, which can be made discrete by assigning outputs above a threshold to one class, and outputs below the threshold to another [42].

Ŷ = X T β̂
RSS(β) = (y − Xβ)T (y − Xβ)

(2.1)
(2.2)

Nearest neighbour classifiers work by using the closest values within the training set to an
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input to predict the class. When given an unknown input, the closest points are identified using
euclidean distance (or some other similarity metric), and the class with the most representation
in that set is the prediction.
Support vector machines function by learning a decision boundary and creating a hyperplane which separates the class with the largest possible perpendicular distance between the
nearest point of each class and the hyperplane (known as margin). Function 2.3 shows how the
margin M is computed by multiplying the weight (w) of the decision boundary by the input
features (xiT ), adding the bias (w0 ), dividing by the norm of the weight (||w||), and multiplying
by the class (yi ). Points closest to the hyperplane are known as support vectors, and only these
change the model. The margin for a hyperplane is found by maximising the perpendicular
distance M between the hyperplane and the closest support vector [42].

M = yi

2.1.2

xiT w + w0
||w||

(2.3)

Multi-class classification

Up to this point, all classifiers discussed function in the binary case – they separate one class
from another, and nothing more. Many real world problems, however, contain more than
just two simple classes, and different classifiers are needed to solve these problems. Some
classification methods can be adapted to n classes easily, such as nearest neighbour. In the
nearest neighbour problem, the procedure is the same as the binary class, only considering
more classes. The class represented by the highest number of neighbours is the predicted one,
whether that is one of two classes or one of twenty [6].
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Other methods require adapting binary classifiers to work as a multi-class classifier. There
are primarily two ways of accomplishing this; one vs one (OvO) where many binary classifiers
decide if an object belongs to one class or another and collectively decide the class, and one
vs all (OvA) where one classifier per class decides if an object is likely to be part of that
class [32]. OvO classifiers make pairwise comparisons between classes, while OvA classifiers
give the probability that an input belongs to any one particular class. In this way, SVM can be
trained to support multi-class problems by modifying the output to be the euclidean distance
from a point to the hyperplane. In an n class problem, n SVMs are trained, and each gives
a distance from a new input to the hyperplane separating their class from the other two. The
class with the largest distance from the hyperplane is the prediction [58].

2.1.3

Performance metrics

There are multiple different ways to measure the performance of a classifier. Many revolve
around the confusion matrix 2.1, which shows, for each instance in the test set, what the true
class and predicted class was. Occurrences along the main diagonal are correct predictions.
True positives are items where the true class and predicted class are both the positive class, true
negatives are items where the true class and predicted class are both negative, false positives are
items where the true class is the negative class but the prediction is positive, and false negatives
are items where the true class is positive but the prediction is negative. In 2.1, there are 45 true
positives, 20 false negatives, 5 false positives, and 30 true negatives [39].
Precision represents the proportion of predicted positive instances that are actually positive,
and is computed by dividing the true positives by the total positive predictions 2.4. Recall
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Truth

Prediction
Positive

Negative

Positive

45

20

Negative

5

30

Figure 2.1: An example confusion matrix, showing true classes in the rows and predictions in
the columns.

Truth

Prediction
Class A

Class B

Class C

Class A

15

2

3

Class B

7

15

8

Class C

2

3

45

Figure 2.2: An example multi-class confusion matrix, showing true classes in the rows and
predictions in the columns.

represents the proportion of positive classes that correctly identified, computed by dividing
the number of true positives by the total items belonging to the positive class 2.5. Accuracy
represents the fraction of correctly predicted items, and is computed by dividing true positives
and negatives by the total number of items 2.6. Please note that in machine learning, the terms
precision, recall, and accuracy each refer to a specific metric and are not the same as their
english language definition.

F1 score is the harmonic mean of precision and recall, computed by dividing the product of
precision and recall by their sum and multiplying by two 2.7. The harmonic mean has the effect
of giving a larger score to cases with both high precision and recall than it would to models
with low precision but high recall or vice versa [39].
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TP
TP + FP
TP
Recall =
TP + FN
TP + TN
Accuracy =
TP + TN + FP + FN
Precision · Recall
F1-score = 2 ·
Precision + Recall

Precision =

(2.4)
(2.5)
(2.6)
(2.7)

The receiver operating characteristic curve (ROC) is a plot of sensitivity versus specificity
as the parameters of classification (such as the probability threshold used to determine the
positive class) are varied. It is often used as a summary of the trade off between the sensitivity
and specificity [42]. Precision recall curves (PR) on the other hand, show precision vs recall
while parameters are varied in the same manner. ROC curves can be misleading in heavily
imbalanced datasets, and PR curves can provide a better evaluation of performance in these
cases [26, 73].
Many of these methods can be adapted to the multi-class case, taking one of a few approaches to integrate all classes into a single metric. Simple multi-class accuracy can be
computed by dividing the total number of true positives for each class by the total number
of instances. Note that in this case, summing the true positives for each class is the same as
summing the true positives and true negatives in the binary case since the number of true negatives for one class is equal to the sum of the true positives for all other classes. Simple accuracy
is just the number of correct predictions divided by the total number of instances. Balanced
accuracy gives equal weight to all classes instead of all instances and is computed by dividing
the number of true positives for each class by the total instances in that class, summing that
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value for all classes, and dividing by the number of classes 2.8. Weighted accuracy on the other
hand, gives weight proportional to the size of the class by multiplying the total number of items
in a class by the weight of the class in the sum, and multiplying the total number of items in
the dataset by the sum of each class’s weight [39].

In the following equations K is the number of classes, i represents a single class, wi is the
weight (frequency) of a single class, and W is the sum of the weights for all classes

BalancedAccuracy =
WeightedAccuracy =

K TPi
Σi=1
Totali

K
TPi
K
Σi=1
wi Totali

WK

(2.8)
(2.9)
(2.10)

Similar to accuracy, Precision, Recall, and F1 score can be computed using either macro,
micro, or weighted averages. Macro averages are the sum of the score for each class divided
by the number of classes 2.11, 2.12, 2.13. Micro averages consider all instances together,
regardless of class differences. Since micro averaged precision 2.14 is the same as micro
averaged recall 2.15, micro averaged F1 score is also the same. Weighted averages are obtained
by summing the per-class value of the score multiplied by its frequency in the dataset [39]. The
main difference between macro averages and micro or weighted averages is that macro averages
treat all classes equally, while the others depend on the relative proportion of each class in the
test set. ROC and PR curves can be adapted to the multi-class case by using the micro averaged
scores.
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K
Precisioni
Σi=1
MacroPrecision =
K
K
Σi=1
Recalli
MacroRecall =
K
MacroPrecision · MacroRecall
MacroF1-score = 2 ·
MacroPrecsion + MacroRecall
K
K
Σi=1
TPi
Σi=1
TPi
MicroPrecision = K
=
Σi=1 TotalColumni TotalInstances
K
K
Σi=1
TPi
Σi=1
TPi
MicroRecall = K
=
Σi=1 TotalRowi TotalInstances

MicroF1-score =

2.1.4

K
Σi=1
TPi
TotalInstances

(2.11)
(2.12)
(2.13)
(2.14)
(2.15)
(2.16)

K
WeightedPrecision = Σk=1
Precisioni · wi

(2.17)

K
WeightedRecall = Σk=1
Recalli · wi

(2.18)

K
WeightedF1-score = Σk=1
F1-scorei · wi

(2.19)

Clustering and Unsupervised learning

Unlike supervised learning, which focuses on predicting a specific label for the inputs, unsupervised learning focuses instead on learning some pattern from a set of unknown inputs.
Since the true output is unknown, there is no true “success” state to benchmark against. Metrics for measuring performance of unsupervised learning usually focus on relative similarity
between observations rather than how close they are to a success state. Clustering is a form of
unsupervised learning in which an algorithm attempts to find groups of inputs which are more
similar to each other than any other input. It is also known as data segmentation, and seeks to
partition the dataset. Clustering uses a pre-defined notion of similarity between points, such
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as euclidean distance between points p and q 2.20. When using euclidean distance, points that
are closer together are considered more similar than points far apart [42].

p
d(p, q) = (p1 − q1 )2 + (p2 − q2 )2 + · · · + (pi − qi )2

(2.20)

Many clustering methods have been developed, and here I will describe a few of the ones
that are relevant to my thesis. K-means clustering uses squared euclidean distance as a similarity measure, and functions by repeatedly re-assigning data points to the group with the nearest
centroid, re-computing the centroid, and repeating until the centroids no longer change. The
initial centroids are selected randomly. Hierarchical clustering, on the other hand, can be either
agglomerative or divisive. In agglomerative clustering, each input starts off as its own group,
and the most similar groups are merged. This step is repeated until the highest similarity between groups is below a pre-defined threshold. Divisive clustering starts the other way around,
with all inputs as a single large group. The group is then split in a way that creates the highest
possible dissimilarity, and this repeats until a threshold is reached [42].
The Louvain clustering algorithm is a graph based method used by the Seurat package (one
of the most cited packages for analysis of scRNA-seq data) [14, 80]. It functions similarly
to agglomerative clustering, but it uses a modularity score instead of similarity. Modularity
2.21 measures the density of links within nodes in a community compared to those between
communities. Louvain clustering starts by creating a network where each node is its own
community, and the links are the distances between nodes. For each node, its neighbours
are examined to see which one could be added to give the largest gain in modularity. Nodes
are only added to a community if they would yield a positive gain in modularity. This is
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repeated until no further improvement is possible (local maximum), and then a new network
is created. In this new network, each community from the original network is a node, and
the links between communities are the sum of the weight of links between nodes in the two
communities. The first phase is repeated, and the algorithm continues until the second phase no
longer results in a change in communities and local maximum modularity is thus achieved [14].
In the following formula, Ai j is the weight of the edge between nodes i and j, ki = Σ j Ai j is
the sum of edge weights attached to node i, ci is the community containing node i, δ(ci , c j ) is 1
if ci = c j otherwise 0, and m = 21 Σ j Ai j

Q=

2.2

ki k j
1 X
[Ai j −
]δ(ci , c j )
2m i, j
2m

(2.21)

Cancer and RNA sequencing

In this section, I provide background for the RNA-sequencing techniques used to source data
and the environment that I have selected data from. Single cell RNA-sequencing (scRNA-seq)
is a new technology that allows us to study cancer and the tumour micro-environment (TME)
with greater precision than ever before. I also review many of the available software packages
that can be used to analyse scRNA-seq data.

2.2.1

RNA sequencing

RNA sequencing (RNA-seq) is an important tool for measuring gene expression. Early versions
of the technology use bulk tissue samples to read the average transcriptome of cells within
a sample. RNA-seq procedures typically involve extracting RNA molecules by lysing cells
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in a sample, enriching the mRNA, reverse-transcribing the mRNA to create a cDNA library,
sequencing of the library through one of a variety of techniques, then computational assembly
of the library into a transcriptome. This bulk-tissue approach is well established and has had
utility in many applications, but it cannot measure gene expression differences between cells
within a single sample. It is unable to resolve specific cell types or information on where a cell
is located within a sample, limiting the precision with which we can study these systems [79].

2.2.2

Single-cell RNA sequencing

All cells begin as generalised stem cells, but become specialised for a certain task or tissue
type through a process known as differentiation. Differentiation changes the gene expression
of these cells in a measurable way, allowing us to infer a cell’s type or function from its expression profile [10]. The previously described bulk RNA-seq methods are unable to capture
gene expression with high enough precision, however, preventing the study of individual cells
within a sample. Single-cell RNA sequencing (scRNA-seq) methods provide tools to separate
cells prior to sequencing and thus capture the heterogeneity masked in bulk methods. There are
multiple different approaches, but all follow the same general procedure 1) sort and separate
cells, 2) lyse the cells, 3) filter and sequence the leftover RNA molecules. Droplet based techniques (such as 10x chromium) use emulsion bead droplets containing sequencing reagents to
separate cells [75, 96], FACS-based methods use fluorescence-activated cell sorting to separate
cells in 96 well plates [75,97], and Fluidigm C1 uses an integrated microfluidic chip to capture
cells from suspension [75].
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Tumour micro-environment

When the mechanisms governing cell death and replication are mutated, the cells can proliferate and invade nearby tissues, becoming cancerous. These mutations affect not only cell
behaviour, but gene expression within a cell, and are thus measurable via scRNA-seq [3]. Unfortunately, tumours are not comprised of entirely malignant (cancerous) cells, and contain a
variety of cells, including immune, malignant, and cells of the tissue of origin – neurons in
a brain tumour or epithelial cells in a skin tumour, for instance (Figure 5.3c) [52, 85]. This
heterogeneity, and the interactions between cell types, affects how cancer progresses, metastasises, and responds to treatment [4,48,59]. Before the advent of scRNA-seq, it was not possible
to fully capture and study this heterogeneity.

2.2.4

Automated analysis of scRNA-seq

While scRNA-seq gives a wealth of data allowing us to study tissues and cancer in new ways,
that same wealth of data is hard to study manually. Several components of scRNA-seq analysis pipelines are already automated through computational pipelines, but other steps remain
a mostly manual process requiring researchers to call commands themselves and provide user
input for many steps, instead of having a single entry point for an analysis pipeline [80, 96].
The following steps are automated.
1. Quality control of reads, in which sequenced reads are filtered for duplicates and their
barcodes are processed to create information about the quality, accuracy, and diversity of
samples [96].
2. Mapping of reads to a reference genome using a sequence alignment algorithm (such
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as STAR) so they can be assembled into gene expression counts. This is important
since the scRNA-seq reads on their own are just sequences of nucleotides containing
no information on gene expression. Only by aligning the individual reads to a complete
transcriptome can we understand how the genes are expressed within the sample [96].

3. Normalisation of expression counts for differences due to factors other than actual expression values. Within sample normalisation corrects for differences in gene length,
while across sample normalisation corrects for differences in sequencing depth. This
prepares the data to ensure that any differences within or between samples are only due
to changes in gene expression [80].
4. Dimensionality reduction via principal component analysis (PCA), t-distributed stochastic neighbour embedding (t-SNE), or uniform manifold approximation and projection
(UMAP) to select only the most relevant features within the data. By selecting the most
relevant features, we can reduce the computational complexity of future steps and filter
out so-called house keeping genes that do not change much between different cells [80].
5. Clustering of cells based on similar expression profiles. This unsupervised learning process allows groups of similar cells to be automatically identified for further study [80].
6. Detection of those genes that are differentially expressed between clusters. This identifies
the genes with the largest changes in expression between clusters of cells so that we can
make inferences about the types of cells within a particular cluster, or changes that have
occurred in cells which have received experimental conditions [80].
7. Visualisation of clusters and/or differentially expressed genes using t-SNEs or UMAPs.
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After these steps are completed, however, the cell types within each cluster are often annotated by hand, using the expression of cell type signature gene sets. These gene signatures
typically come from previously sequenced cells of a known type and are strongly expressed
within cells of that type [80]. Several methods to automate the process of cell type identification have been proposed, and fall mainly into two groups; cell based methods which do not
require a clustering step, use supervised learning to train a classifier on a set of known cells
before being fed a list of unknown cells for prediction, and cluster based methods which use
the gene expression profile of a cluster of cells along with either previously identified cell type
signature gene sets or a group of annotated reference clusters [1, 80].

Some cluster based methods are as follows:
Over-representation analysis (ORA)

searches the differentially expressed genes within a

cluster for over-representation of cell type signature gene sets. A P value of independence for
each gene set is computed, and the gene set with the highest probability that is still significant
is the predicted cell type [38].

Gene set enrichment analysis (GSEA)

ranks the genes within a cluster by expression level,

then compares gene sets to the ranked list to see where on the list the genes are located. If genes
are primarily found towards the bottom of the list, they are related to the cells phenotype. In
this way, gene sets clustered primarily at the bottom of the list can be used to predict the cell
type [81].

Gene set variation analysis (GSVA)

builds on GSEA by using a sample distribution and

expression level statistic to rank genes. For RNA-seq, a poisson kernel is used to estimate per-
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gene expression level statistics, which are used to build gene sets from sample-wise enrichment
scores. A random walk procedure is then used to asses the enrichment scores of individual gene
sets and predict cell types [41].

CIBERSORT uses a matrix of cell-specific expression signatures. Cell type prediction is
performed via deconvolution using support vector regression to select genes from the input
matrix. Support vector regression is like SVM, but identifies a hyperplane which fits as many
data points as possible within a constant distance. SVRs optimise both a loss function and a
penalty function to yield a prediction [64].

METANEIGHBOR uses meta-analysis via neighbour voting to annotate cells. A pairwise
spearman correlation based on the expression of gene sets between cells to be compared is used
to create a network in which nodes are cells and edges are weighted by strength of correlation
between cells. The labels for some cells are then hidden, and the unhidden ones are used to
predict the cell type labels via neighbour voting [22].

Adobo uses a set of previously identified marker genes to measure an activity score for each
cluster. Cell types are ranked based on the activity of their marker genes within the cluster,
and the top ranking cell type is the prediction. Marker genes present in more than one cell type
are down-weighted, giving more credence to those marker genes that can be used to identify a
unique cell type [30].

scCATCH identifies marker genes for each cluster using a pairwise correlation between all
clusters. Marker genes for a cluster have a significantly greater expression in that cluster com-
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pared to all others. Identified marker genes are then compared to cell type signature gene sets
in the CellMatch database in order to predict cell types [76].

Some cell based methods, broken into categories of similar algorithms, are as follows:
Neural networks

Automated Cell Type Identification using Neural Networkds (ACTINN)

uses a neural

network with one input layer, three hidden layers, and a single output layer to predict cell
types. The input and hidden layers use a rectified linear unit (ReLU) activation function and
softmax is used for output [57].

Label Ambiguous Domain Adaptation (LAmbDA) is a transfer learning framework, using
a feed-forward neural network with one hidden layer to integrate multiple datasets for prediction [46].

Cell BLAST is a neural network based generative model. A decoder neural network runs
a generative process by learning a projection of the transcriptome onto a low-dimension cell
embedding space. Batch effects are corrected using adversarial alignment. For prediction, and
unknown input sample is projected onto the same low-dimensional space [18].

Single-cell ANnotation using Variational Inference (scANVI)

is based on a hierarchical

bayesian model and distributions which are specified by neural networks. The expression of
each gene in a cell is modelled as a zero-inflated negative binomial distribution, and a neural
network maps the dataset onto the distribution’s variables. The mapped variables are used to

22

Chapter 2. Background

estimate differential expression and cell types [92].

Support vector machines

SVM and SVM with rejection

are standard multi-class support vector machines as de-

scribed earlier. SVM with rejection adds a threshold to the prediction probability, such that
any prediction with a probability below the threshold is rejected, and that cell is labelled as
unknown [67].

scPred

uses singular value decomposition to create orthonormal, linear combinations of

genes. Principal components explaining more than 0.01% of the variance are selected for
future steps, and the most informative of these components are selected using a Wilcoxon test.
K-fold cross validation is used to train a support vector machine, using the principal components instead of the full dataset [5].

Nearest neighbours

K-Nearest Neighbours (KNN 9) is a nearest neighbour classifier as described earlier, using
nine neighbours [67].

Nearest Mean Classification (NMC) is similar to nearest neighbours, but instead of assigning an input to the class with the most neighbours, it assigns it to the class whose mean is
closest to the input [67].

scmap-cell maps cells from a query to a reference sample using product quantisation. Cosine distance helps reduce batch effects compared to euclidean distance, and sub-centroids are
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created from the reference cells and used to improve run time compared to using all reference
cells [49].

scmap-cluster

is similar to scmap-cell, but a single centroid for each cell type is computed

and used for classification. Like NMC, the class with the closest centroid is the prediction [49].

Random forests

Random forest (RF)

uses a collection of decision trees (a forest of them) to create predic-

tions. Each tree uses a random subset of the features in the input, in my case the genes, as
prediction criteria. Bootstrapping is used to combine the results of all trees within the forest to
a single prediction [67].

SingleCellNet

uses top-pair transformation to turn the expression matrix into a binary matrix

of selected genes from those within each cell type of the training set. These binary matrices
are used as input for a random forest classifier [82].

Discriminant analyses

Linear discriminant analysis (LDA) and LDA with rejection

model class density as a

multivariate gaussian distribution and assumes all classes have a common covariance matrix.
It then creates a new hyperplane to project data onto in such a way that the distance between
the mean of each class and a centroid for the entire dataset is maximised and the variance
within each class is minimised. By optimising both criteria, the separation between classes
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is maximised. Similar to SVM with rejection, LDA with rejection used a threshold to reject
predictions with low probability [67].

Single-cell IDentification (scID) uses LDA to identify related cell types between datasets,
regardless of batch effects or sample quality. Prior to LDA classification, feature selection is
performed by generating gene signatures for each class in the reference data and weighting each
feature. A OvA approach for multi-class classification is used to classify cells by examining
the probability of an input belonging to each class according to the weighted gene signatures.
Predictions are the classes with the highest probability [15].

Others

Classification of single cells by transfer learning (CaSTLe) uses transfer learning. Feature
selection is performed by removing all genes which are not present in both the training and
testing sets or are rarely expressed, then selecting the 100 features with the highest expression
and the 100 features with the highest mutual information score. An XGBoost classifier is
trained using these features and used to classify input data [54].

CHaracterization of cEll Types Aided by Hierarchical classification (CHETAH) creates
a reference profile for each cell using the average logarithm of gene expression. Hierarchical
clustering with average linking yields a classification tree which is then used to classify inputs
by proceeding from the roots to the leaves of the tree. The branch of the tree most related to
the input cell is selected until the decision confidence falls below a threshold [25].
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compares reference cell types to query cells using a correlation framework. Using

only the most variable genes, a spearman correlation is repeatedly computed, selecting only
the top cell types in each iteration until only a single cell type remains. This final cell type is
the prediction [7].
The TME is complex, and not all methods described here are designed specifically with
this complexity in mind. Some methods have functions created for cancer cells [25], but most
do not. The basic gene expression patterns may not differ between healthy and malignant cell
types, but the expression profile of malignant cells may be noisier due to mutations [70]. Many
of these algorithms have been benchmarked when predicting healthy tissues, but not when
predicting TME samples [1, 26].

Chapter 3
A Framework for Characterising
Performance in Multi-class Scenarios
In this chapter, I propose a few key principles that can be used to better understand multi-class
classifiers and how they perform on a variety of datasets, including the following:
• Grouping similar classes into categories for easier study.
• Re-sampling imbalanced data to test the effect of the imbalance on one or more classifiers.
• Treating per-class performance metrics as features that can be used to study the characteristics of one or more classifiers or datasets using unsupervised learning.
• Grouping the smallest classes across multiple datasets into a single plot in order to examine how well each classifier performs on under-represented classes.
• Simulating new sub-populations while training your data to mimic the presence of sim26
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ilar yet distinct sub-populations in real-world problems, such as malignant cells from
different cancer patients.

3.1

Multi-class problems

Understanding performance in multi-class classification problems can be complex, and becomes more complex as the number of classes increases. Many metrics are based on the confusion matrix (2.1, 2.2), a table which displays instances that are predicted to be a class on
one axis, and instances that are actually that class on the other axis [39]. Correct predictions
lie along the main diagonal of the matrix. The confusion matrix is a comprehensive way to
view performance of a classifier, as it shows a simple summary of the predictions made – if
a classifier has most of its values along the main diagonal it can be considered good – and
it gives a complete picture of all the different ways a classifier makes mistakes. However, it
is impractical for comparing many classifiers, especially in a multi-class scenario where each
confusion matrix will have many rows and columns. From the confusion matrix, many simplified performance metrics can be calculated, but not all are suited for a multi-class problem.
Simple accuracy 2.6 gives equal weight to all individuals, which is well suited if one is only
interested in making as many correct predictions as possible without care for the distribution
of predictions among classes [39]. In a balanced multi-class scenario, high accuracy could
be achieved by predicting most classes correctly and completely failing to predict a small
set of classes. If the classes are sufficiently imbalanced, high accuracy could be achieved
by predicting the same class one hundred percent of the time. Balanced 2.8 and weighted
accuracy 2.9 both provide improvements — by giving equal weight to all classes instead of
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individuals and by giving weight proportional to the size of the classes, respectively — but
neither works well for every multi-class problem. If, for instance, it is more desirable to predict
many individuals correctly, one may wish to use balanced accuracy, but if it is more desirable
to predict many of the classes correctly, weighted accuracy should be used.

In the binary case, F1 score 2.7 is often used, but must be modified for multi-class evaluation. This is commonly done by computing the Macro 2.13, Micro 2.16, or Weighted average
2.19. Just like accuracy, balanced accuracy, and weighted accuracy, neither is perfect in all
cases. In my study, for instance, one dataset is heavily imbalanced, with the largest class containing approximately 45% of all samples, and the smallest only 0.00015%. Few algorithms
are able to correctly predict the small classes in this dataset, and depending on which averaging
technique is used, results will be quite different. Macro average will be low, dragged down by
the small, hard to predict classes. Weighted and Micro average will be higher, since less weight
is given to these small classes. In both cases, the complete story cannot be captured by a single
score.

Few other studies recognise the shortcomings of these metrics when studying multi-class
problems, and may not paint an accurate picture of their classifiers’ performance – whether the
paper presents a new method or compares existing ones. In order to improve the comparison
of multi-class classifiers, a framework to capture the many aspects of performance is needed.
Here I propose such a framework, and provide examples of how it can be used.

3.2. Data collection
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Data collection

In order to properly asses these problems and develop new classifiers, a wealth of data is required. I collected a group of datasets for my scRNA-seq studies and built a framework for
accessing this data that can be applied to other formats – as my colleague Arrian GibsonKhademi is doing with his scATAC.Explorer package [35]. This data collection framework
allows researchers to gather their data and present it to others in an easily accessible format,
thus lowering the barrier to both the development of new methods and testing of existing methods.

3.3

Framework

In order to fully evaluate the performance of a multi-class classifier, users need to understand
how the classifier performs in all cases, such as when classifying a balanced or imbalanced
dataset, when classifying an under-represented class, or when classifying a new sub-population
of the data type that may be significantly different from the training data (such as a new cancer
patient with a different TME). To facilitate this, I have developed a framework for benchmarking multiple algorithms on many classes.

3.3.1

Categories of classes

One way to better understand the performance is to simply look at per-class scores (such as
precision, recall, and F1 score) instead of overall scores for a classifier. This can work when
the number of classes, datasets, and algorithms is small, but as the number of performance
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parameters increases so does the complexity of the visualisations needed to understand and
compare these scores. Grouping similar classes into categories reduces the number of classes
to compare between, and can help identify patterns in the performance of a method. In my
study, examining categories of classes allowed me to recognise which algorithms are better
able to identify malignant cell types compared to non-malignant by grouping all non-malignant
cell types and comparing two values instead of many more.

Considering similar classes as a single category may also be useful in scenarios where
some classes are subclasses of another class. The subclasses many not need to be predicted
separately, but they may be easier to identify when a classifier considers their features separately. For instance, when classifying galaxies, one may be interested in how well planets are
classified, but not specifically how well a classifier predicts gas giant vs terrestrial planet [91].
Grouping the gas giant and terrestrial planet classes into a single category allows specific information to be provided to the classifier while only considering a single performance value
during review. Similarly, when studying the tumour micro-environment, helper T Cells and
memory T Cells may be grouped into a single T Cell category – allowing the classifier to use
marker genes specific to the respective cell types as separating features, yet only reviewing a
single score.

Creating the categories requires knowledge of the specific prediction space (i.e. that gas
giants and terrestrial planets are similar because they are planets, or that T Cells and B Cells
are both immune cells), but given a list of similar classes, the category performance can be
obtained by taking the median or mean of all classes belonging to that category.
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Subsampling of imbalanced datasets

Often, the classes studied in a multi-class classification problem are imbalanced. Some classes
will have many examples present, and others will have very few. Certain algorithms may
perform better or worse when classes are imbalanced, since the largest classes can mask the
presence of the smallest. When a loss function that weights each training instance equally is
used to train a classifier, a greater reduction in loss can be achieved by improving prediction
ability on a class with more samples present, leading to improved performance on overrepresented classes [42]. In some problems these under-represented classes do not strongly affect
the results, but it is nonetheless important to identify algorithms which are able to successfully
classify under-represented classes.
Up or down-sampling is often used to remedy this when studying classifiers but this is
impractical in real-world scenarios – down-sampling throws away potentially useful training
data, and up-sampling could lead to over-fitting for under-represented classes [13]. Thus, it is
necessary to recognise which algorithms are affected by imbalanced data while benchmarking.
In order to identify these algorithms, I created simulated balanced datasets by sampling the
imbalanced data with replacement prior to splitting into training and testing sets. Samples are
randomly taken from each class with replacement until all classes are an equal size. The size
chosen should be larger than the smallest classes and smaller than the largest classes to avoid
throwing too much information away, and reduce the effects of over-fitting. The classifiers
are then re-trained and tested on this data, and the per-class F1 Scores are subtracted from
the original scores. These differences can be clustered together, allowing the identification of
algorithms which see a large change – and thus have their performance drastically affected by
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the class imbalance – from the original experiment.
In my tumour micro-environment study, this technique was used in Figure 5.7. Many of
the datasets I collected were extremely imbalanced (Figure 5.8), and it is likely that any reader
using my results to select an algorithm would also have imbalanced data. By clustering the
change in performance on a simulated balanced dataset, I was able to recognise which algorithms are the most stable on imbalanced dataset and provide a better recommendation because
of it.
Considering the galaxy classification case, this has a similar utility. Galaxies do not have
a consistent mixture of stars, planets, asteroids, and the like, making it important to select
classifiers that are not likely to be affected by an over-representation in one class [91].

3.3.3

Performance signatures

Users benchmarking multiple algorithms may be interested in finding groups of algorithms
that have similar classification ability, potentially to find a set that need improvements before
they are valid for a new type of data, or to find a set which has good performance in order to
recommend their use. In order to facilitate this, the per-class scores can be used as a “performance signature” for clustering. Each classifier is treated as an instance and class is treated
as a feature whose value is given by the performance of the classifier on that class, allowing
automated recognition of patterns within a set of algorithms or datasets. In my experiments I
used F1 score as the evaluation metric for each class, but other metrics could be used instead
and the concept remains the same.
This technique is used multiple times in my study; when studying algorithms for stability
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on imbalanced data (figure 5.7) and when identifying which algorithms are able to recognise
under-represented cell types (figure 5.10). Clustering the change in F1 score on each class
when training on artificially balanced data I was able to identify algorithms which do not have
consistent performance in these cases. Hierarchical clustering of per-class F1 scores was able
to identify which algorithms are able to successfully identify all under-represented classes,
which are unable to identify the most extreme under-represented classes, and which are unable
to identify any under-represented classes.

3.3.4

Under-represented classes

When benchmarking classification algorithms, it is important to recognise which algorithms
are able to predict all classes instead of only the most recognisable ones. Weighted average F1
score is a fantastic tool for summarising prediction results, but in order to tell which algorithms
predict all classes more data is needed. In order to recognise which algorithms are able to
identify the most under-represented classes in my scRNA-seq data, I created a plot which
contains a mixture of the smallest cell types in all eight datasets and grouped the algorithms
according to their performance signature (figure 5.10). This technique allows viewers to easily
see not only how well an algorithm predicts a class, but the size of the class and how large a
class needs to be before an algorithm is able to identify it.
In some scenarios, small classes can have a large effect on the decisions made using the
predictions. In cancer studies, identification of a small treatment-resistant malignant cell population could be the difference between curing a patient and simply leaving them in remission
with a disease that is harder to treat next time around if that small treatment-resistant population
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multiplies into a larger and more dangerous tumour.

3.3.5

Patient training simulations

When developing or benchmarking classifiers, it is common to use cross-validation where a
percentage of the samples are randomly selected for use in training and the rest are used for
testing [16]. This is repeated multiple times to ensure that an algorithm is not over-fitting
the training set. This works in relatively uniform datasets, but may not always be perfectly
generalisable. In cancer for instance, each patient may have similar sets of immune, nonmalignant, and malignant cell types, but the mutations that arose and lead to malignant cells
are unlikely to be similar [3, 52]. In a clinical setting, a classifier will have no prior knowledge
of a patient’s unique mutations before it predicts cell types. Randomly selecting cells for
training could lead to some of a patient’s cells being present in both training and testing sets,
allowing the algorithm to “cheat” by learning of a mutation before it would actually see it in a
real scenario.
To remedy this, I modified the typical cross-validation process slightly by creating groups
where each patient is always in either the training set or testing set but not both. This allows
users to test whether or not their algorithms will generalise properly in a clinical setting (figure
5.9).

3.3.6

Other visualisations

These techniques are not as specific to any particular multi-class problem but are applicable to
a variety of data visualisations.
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• Violin plots are sometimes used to show the distribution of numeric data. These work
well for some scenarios, but I found they had too much of a “smoothing” effect on my
data. To remedy this, I overlaid box plots with jitter plots, allowing readers to see both
quartile and distribution data without smoothing the large regions with no data points.
(Figures 5.6c and 5.6d)
• My study required many comparisons between two experimental conditions that produced two dimensional matrices. I found that subtracting one matrix from the other and
using a diverging colour palette centred at zero provided a easy way to pick out the most
prominent changes in a large dataset. When comparing methods for multi-class prediction, this style of plot can highlight per-class changes between classifiers or help identify
areas of improvement when developing new classifiers. For instance, in figure 3.1, I
am comparing the ability of different algorithms to perform similarly when the relative
proportions of the classes are changed. This diverging colour palette allows one to see
that Cell BLAST and scmapcell see large increases in performance on more classes than
other algorithms, and scID sees more decreases than other algorithms. This particular
study is discussed more in chapter 5.

36

Chapter 3. A Framework for Characterising Performance in Multi-class Scenarios

Figure 3.1: A heatmap showing the change in performance of different algorithms on different
cell types when the relative proportions of the classes are changed. Red values are show an
increase in F1 score compared to the original imbalanced classes, and blue values show a
decrease.

Chapter 4
Data Collection and TMExplorer

4.1

Introduction

Single-cell RNA sequencing (scRNA-seq) is a new technology that has emerged as an important tool to measure gene expression for individual cells, enabling the examination of cellular
heterogeneity and tissue composition with incredible precision. This has been particularly
applicable in cancer research for the study of tumour composition, heterogeneity and phenotype, all of which are directly impacted by the tumour micro-environment (TME). TMEs are
composed of different stromal and cancer cell types whose interactions likely dictate different
aspects of tumour behaviour, such as metastasis [21, 53, 85, 86]. Combined with scRNA-seq
analysis methods, scRNA-seq enables us to dissect the TME into individual cells and investigate the different cell subpopulations that exist. Such investigations into the TME are becoming
increasingly important, as tumour composition and heterogeneity can influence cancer progression and the outcome of cancer therapy [23, 45, 51, 66, 85–87].
With the advancement of scRNA-seq in cancer research, the number of TME datasets that
37
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are generated continues to increase, yet they can be difficult to access. Raw sequence reads
generated by scRNA-seq can be shared through online archives, such as the Sequence Read
Archive (SRA) [77], however they exist as large files that require further processing to be analysed, making data access a challenge. Already processed scRNA-seq data containing gene
expression information can be accessed through online archives, such as the Genome Expression Omnibus (GEO) [27], and can be more easily downloaded for use in one’s own analysis. Furthermore, to manage the growing abundance of publicly available scRNA-seq data,
proper quality control and curation of datasets must be done [17, 31]. Currently, several online databases offer curated collections of public scRNA-seq datasets, such as PanglaoDB [31],
scRNASeqDB [17], JingleBells [63] and the Single Cell Portal created by the Broad Institute
of MIT and Harvard [65]. Most existing scRNA-seq databases include a mixture of samples
from normal tissues and tissues affected by cancer or other diseases [17, 31, 63], while others
focus primarily on samples from normal tissues [71, 90]. A recently published toolkit called
CReSCENT [61] contains only cancer scRNA-seq data, however it mainly acts as a cancer
data analysis pipeline rather than a database. A comprehensive database for the collection
and sharing of TME scRNA-seq datasets from a range of tumour types does not yet exist,
and researchers interested in using publicly available TME data must search through several
databases to collect relevant datasets for their study. A database of TME scRNA-seq samples
will thus streamline the data collection steps required for researching cancer at a single-cell
level, lowering the barrier for entry to this type of study.
It is likewise important that scRNA-seq databases are designed to facilitate streamlined
data collection and analysis. This can include a search tool that allows users to select datasets
based on desired characteristics. While existing databases include search tools, they provide
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few options in characteristics users are able to search for and often require users to browse
through a metadata table prior to selecting datasets of interest. Furthermore, they are designed
as web-based tools, and thus are not intended to be integrated into workflows [17, 31, 63, 65].
Workflow integration would enable users to access data directly in their pipelines, thus automating the data collection process and increasing analysis efficiency. A scRNA-seq database
that is provided as an R-package and contains a comprehensive search tool which allows users
to select datasets based on a wider variety of characteristics would make the data collection
process easier for researchers.
Here, we present a curated collection of tumour scRNA-seq datasets made available as an
R-package called TMExplorer. TMExplorer contains publicly available scRNA-seq datasets
specific to TMEs from various tumour types collected from different scRNA-seq studies [9,19,
21, 23, 24, 28, 33, 36, 37, 45, 47, 50, 51, 53, 55, 60, 66, 68, 69, 84, 85, 87–89, 93–95] and online
databases [8, 27]. In addition to gene expression data, TMExplorer contains the corresponding
cell type annotations and gene-signature information for several datasets, and provides a search
tool that enables users to search for multiple datasets according to 13 different characteristics
(Table 4.1). When selecting datasets, users can review the metadata table first or they can retrieve datasets that match specific criteria without having to browse through the metadata table.
While online databases require users to download a given dataset prior to use, TMExplorer
allows users to access and search available datasets within R. Users can thus input the data
directly into existing pipelines with only a few commands. Each dataset can be used directly
within R as a SingleCellExperiment object, or exported as a gene expression matrix in multiple formats for use with other applications. Users interested in validating scRNA-seq analysis
algorithms, as they apply to TME data, can easily access this information through TMExplorer
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and incorporate it into their pipelines. Altogether, TMExplorer makes it easier for researchers
to access and share TME scRNA-seq datasets, facilitating the study of TMEs at the single-cell
level in the field of cancer research.
Table 4.1: A list of search parameters that can be passed to queryTME in order to filter the
available datasets.
Search Parameter
geo accession
score type
has signatures
has truth
tumour type
author
journal
year
pmid
sequence tech
organism
sparse
download format

4.2
4.2.1

Description
Search by GEO accession
Search by type of score available
Search by presence of cell type signature gene sets
Search by presence of cell type annotations
Search by type of tumour
Search by first author
Search by publication journal
Search by publication year
Search by PMID
Search by sequencing technology
Search by source organism
Return expression in sparse matrices
Specify a list of score formats to download. Additional
formats will be stored in altExps

Methods
Data collection

In order to collect the datasets, we searched the National Center for Biotechnology Information
(NCBI) [29] for relevant scRNA-seq studies using the following keywords: single cell RNA
sequencing, tumour, cancer, tumour micro-environment, and malignant. We then carefully reviewed the published literature and any associated data to confirm if they matched our criteria.
Datasets were included in our data collection if they were publicly available as processed data,
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were generated by scRNA-seq and if they consisted of TME expression data. A total of 27
datasets originating from different types of human and mouse tumours were collected from
online sources such as the NCBI’s Gene Expression Omnibus (GEO) [27], ArrayExpress [8],
and Github [44]. Out of the 27 datasets we collected, 23 datasets originated from human tumours and 43 datasets originated from mouse tumours. Descriptions of the collected datasets
are provided in Table 4.2. Metadata for each dataset, such as tumour type and number of cells
sequenced, were collected from descriptions in the corresponding publications and/or from the
online sources that the datasets were obtained from. If publicly available, I also retrieved celltype annotations and/or gene signature information that accompanied the datasets. All data is
hosted on FigShare [78] under the TMExplorer project.
Table 4.2: List of tumour micro-environment scRNA-seq datasets included in TMExplorer.
Dataset

Cancer
type

Sequencing
Technology

Number
of cells

Number
of genes

Annotation
available?

Patel et al.
Science 2014

Primary
Glioblastoma
Metastatic
melanoma
Oligodendroglioma
IDHmutant
astrocytoma
Colorectal
cancer

SMART-seq

1,456

5,796

Yes

Gene
signature
available?
No

SMART-seq2

4,645

23,686

Yes

Yes

SMART-seq2

4,347

23,686

Yes

Yes

SMART-seq2

6,341

23,686

No

No

Fluidigm C1

376

57,241

Yes

Yes

Fluidigm C1

564

57,915

Yes

Yes

Tirosh et al.
Science 2016
Tirosh et al.
Nature 2016
Venteicher et
al. Science
2017
Li et al.
Nature
Genetics
2017
Chung et al.
Nature
Commun
2017

Primary
breast
cancer
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Puram et al.
Cell 2017

Giustacchini
et al. Nature
Med 2017
Filbin et al.
Science 2018
Jerby-Arnon
et al. Cell
2018
VanGalen et
al. Cell 2019
Ting et al.
Cell Reports
2014
Miyamoto et
al. Science
2015
Jordan et al.
Nature 2016

Azizi et al.
Cell 2018
Lambrechts
et al. Nature
Med 2018
Davidson et
al. Cell
Report 2020
Peng et al.
Cell
Research
2019
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Head and
neck
squamous
cell
carcinoma
Chronic
myeloid
leukaemia
H3K27mutant
glioma
Melanoma

SMART-seq2

5,902

21,884

Yes

Yes

SMART-seq2

2,287

23,384

No

No

SMART-seq2

4,059

23,686

Yes

No

SMART-seq2

7,186

23,686

Yes

Yes

Acute
myeloid
leukaemia
Pancreatic
circulating
tumour
cells
Prostate
circulating
tumour
cells
Breast
circulating
tumour
cells
Breast
carcinoma
Non-small
cell lung
carcinoma
Melanoma

Seq-well

38,410

27,899

No

No

Tang protocol

187

29,018

No

No

ABI SOLiD

169

21,696

No

No

SMARTer

74

23,368

No

No

InDrop

46,016

14,875

No

No

10x
Genomics

51,775

22,180

Yes

Yes

SMART-seq2

6,423

26,946

No

No

10x
Genomics

57,530

24,005

Yes

Yes

Pancreatic
ductal
adenocarcinoma
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Darmanis et
al. Cell
Reports 2017
Kumar et al.
Cell Reports
2018
Zhao et al.
BMC Med
Genomics
2019
Chen et al.
Cell
Research
2020
Lin et al.
Genome
Medicine
2020
Gillen et al.
Cell Reports
2020
Zhang et al.
Cell Reports
2019
Yeo et al.
Elife 2020
Gao et al.
Nature
Biotechnology 2021
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Primary
glioblastoma
Mixed
cancer

SMART-seq2

3,589

23,465

No

No

10x
Genomics

10,573

27,998

No

No

Glioblastoma
cell line

Fluidigm C1

134

21,209

No

No

Nasopharyngeal
carcinoma

10x
Genomics

48,584

24,720

Yes

No

Pancreatic
ductal
adenocarcinoma
Ependymoma

10x
Genomics

14,926

22,217

No

Yes

10x
Genomics

18,500

23,580

Yes

No

Gastric
cancer

10x
Genomics

56,440

22,910

No

No

Breast
cancer
Anaplastic
thyroid and
breast
cancer

10x
Genomics
10x
Genomics

13,745

31,053

No

No

36,201

33,964

No

No

Data curation

Datasets found on GEO often contain extra information such as Ensemble ID or chromosome
region in additional rows or columns. I modified all datasets using R to ensure they followed
a similar genes-by-cells format with the gene column serving as an index. If any dataset is
published as separate samples, samples are merged into a single file with a suffix identifying the
sample appended to cell IDs, so users may separate the samples and perform batch correction
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if necessary. Having a similar format for datasets reduces the preprocessing required to use
this data in other analysis pipelines.
There are three main components to each dataset in our database: 1) gene-by-cell expression matrices; 2) cell type labels; and 3) gene signatures. The cell type labels are R dataframes
with two columns; one contains every cell barcode present in the expression matrix and the
other one contains that cell’s type. The gene signatures are stored in R dataframes containing
one column per cell type, with a list of genes that are differentially expressed by that cell type
and reported in the original paper in which each dataset was first introduced. All data for each
dataset is accessible within a single object in order to make it as easy to use as possible.
Since R BioConductor has existing infrastructure for working with scRNA-seq data [43,
56], I used it as the platform to build our package upon. In order to maintain compatibility with
existing Bioconductor software, I return all datasets as SingleCellExperiment objects [56].
Figure 4.1 shows the structure of a SingleCellExperiment object, where the expression data is
stored as a named assay, cell type labels (if present) are stored under colData(), and all other
information is stored in a metadata list.
• Expression Data:Named assays allow certain formats to be easily accessed with getter
functions such as counts() and tpm(), while other formats can still be accessed with the
assay() getter function [56]. All SingleCellExperiments have one assay named according
to the type of score (e.g. Counts and TPM) represented in that object. Calling assay()
returns an expression matrix with rows of genes and columns of cells
• Cell Type Labels:ColData stores metadata for the columns in the assay matrix. In our
case this refers to the cell type annotations, if they are available. ColData is a dataframe
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that always has one row for every column in the assay matrix, ensuring that there is a
label present for every cell. If the cell type is not available for a given cell, it is labelled
as “unknown”.

• Metadata:The metadata list serves to store any other information that does not fit into a
pre-existing attribute of the SingleCellExperiment object, and is accessed with the metadata() function. This named list contains the signature gene sets, available score types,
tumour and host organism type, sequencing technology, author, and all other descriptive
information as strings. All information that is available in the metadata table can be
accessed by calling the query function of TMExplorer (i.e. queryTME) with the metadata only parameter set to true.

4.2.3

Metadata

After collecting the datasets, corresponding metadata was compiled into a table which serves
as the core of the package. The metadata table contains information such as GEO accession,
author, journal, year, PMID, sequencing technology, expression score type(s), source organism,
type of cancer, number of patients, tumours, cells and genes, and the database that the data was
obtained from. All items in the metadata table were chosen as either entities that distinguish
one dataset from the others or criteria that may make a dataset or group of datasets interesting
to researchers (e.g. a specific tumour type or availability of cell labels or gene signatures).
Users can view the available data using the metadata table and decide which dataset best fits
their needs.
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Single Cell Experiment

Assay

ColData

• Matrix or
dgCMatrix storing
the genes x cells
expression data

• DataFrame
containing the cell
type labels

• Assays are named
according to their
score type

Metadata
•
•
•
•
•
•
•
•
•
•
•
•

Cells
Genes
Signatures
PMID
GEO Accession ID
Technology
Score type
Organism
Author
Tumour Type
Tumours
Patients

Figure 4.1: The format of the SingleCellExperiment objects containing TME datasets. The
Assay is a matrix or dgCMatrix containing the gene expression table, named according to the
type of score (i.e. an Assay containing raw counts would be named “Counts”); colData is a
DataFrame with the number of rows equal to the number of columns in the Assay and describes
the cells in the dataset; Metadata is a named list of additional metadata objects describing the
dataset. A SingleCellExperiment object may contain one or more AltExps, which are nested
SingleCellExperiment objects containing a different score type in the Assay.

4.2.4

Database query

TMExplorer provides a query function (i.e. queryTME) that users can employ in order to select
multiple datasets based on their desired characteristics. For example, users can select specific
studies by PMID or GEO accession, or filter subsets by sequencing technology, whether cell
type labels or cell type signature gene sets are available etc. Sequencing technology, score type,
organism, tumour type, and year were all chosen as search parameters because they represent
differences in the type of data and make it easier to find data that fits the needs of different
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studies. Some datasets may publish multiple tumour types under the same study, TMExplorer
is able to handle this by having multiple rows of different datasets from the same study. In these
cases, users will need to provide multiple search parameters to select a single row, for instance
the GEO accession and tumour type for a study that contains multiple cancers. I have also made
it possible to search for datasets for which the cell labels and gene signatures are available. This
facilitates developing and testing algorithms that require specific types of dataset information.
For example, testing cell classification algorithms requires cell labels that can be used as a gold
standard, and many existing algorithms require gene signatures that represent the cell types in
the dataset [41, 64].

4.2.5

Alternative experiments

For several datasets, gene expressions are available in multiple score types including raw counts
and normalized data by FPKM, TPM or CPM. In order to store each dataset in multiple score
types, I used nested SingleCellExperiments objects with the alternative experiments (altExps)
concept. Alternative experiments are guaranteed to have the same dimensions as the primary
object, but can be kept separate for use in other pipelines [56]. This allows users to download
multiple types of scoring for use in different steps of analysis while still being able to access
each dataset through a single object. Being able to download multiple score types allows our
datasets to be used in a variety of algorithms that require a specific type of score, and keeping
them separated as nested objects prevents accidentally applying an algorithm to the wrong
score type.
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Dense vs. sparse data formats

In order to reduce the memory requirements for working with large datasets, expression data is
optionally available as a sparse matrix. Sparse matrices are stored using the dgCMatrix class
from R Matrix [12]. This reduces memory usage by only storing non-zero expression values.
With sparse matrices, the memory required to store a dataset is reduced by as much as 8 Gb for
a dataset with 51,775 cells and 22,533 genes. It should be noted that not all software packages
are compatible with sparse matrices, and converting large datasets from sparse to dense may
crash R on machines with low memory. Thus users should confirm that their algorithms support
sparse matrices before using them. By default, TMExplorer returns dense matrices to avoid
these problems.

4.2.7

Exporting data in multiple formats

Several tools for scRNA-seq analysis are written in R and therefore a SingleCellExperiment
object can easily be incorporated into these pipelines and tools. However, many other analysis
tools are written in Python or as webapps [2, 30, 61]. To facilitate the use of TMExplorer with
these tools, I wrote a function saveTME that writes individual TME datasets to disk as CSV
or Matrix Market files, depending on whether data was loaded as dense or sparse matrices
by queryTME, respectively. SaveTME takes a SingleCellExperiment object and a path to an
output directory as parameters and saves the gene expression matrix, cell type labels, and cell
type signature gene sets to disk. The resulting files can then be converted as needed and used
in other applications.
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Adding new datasets

We keep TMExplorer updated with new datasets as they get published. Additionally, users of
the package doing their own novel research will have access to an issue template on Github
where they can submit their data for inclusion. The interested users will need to provide their
scRNA-seq data as raw counts or normalized data and the corresponding metadata. Since
TMExplorer is open source, those same users can create a fork of the repository and build it
from source with their own data for pre-publication work. Users wishing to fork the repository
for their own data need only replace or add to the metadata table used by the package and update
any documentation or function names to reflect the new data. If users are adding new TME
data, no functions need to be changed since this package already uses TME data, but users
could use any other type of single-cell sequencing data (such as scATAC seq) by changing
documentation and functions to reflect that new data.

4.3
4.3.1

Results
Overview of the TMExplorer package

To make it as easy as possible to integrate TMExplorer into other pipelines, all interactions
with the package are done directly in R. Here, the queryTME function serves as the primary
interface for the package, allowing users to view the metadata for all available datasets, or select
a subset of datasets according to descriptive criteria (Figure 4.2a). queryTME provides a set of
parameters (Table 4.1) used to select a subset of datasets according to characteristics. To review
the available datasets, the metadata only parameter should be set to TRUE when querying the
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package, and a table describing the datasets will be returned instead of the datasets themselves.
The search parameters can be used to find relevant data without requiring users to review the
metadata table first, lowering the barrier for use. For example, users looking for a certain type
of cancer, such as melanoma, can search using queryTME(tumour type=”Melanoma”) without
needing to first examine the metadata for datasets containing melanoma cancers.
After querying the database, a list of SingleCellExperiment objects are returned. The objects in this list can then be passed to any other algorithms that accept a SingleCellExperiment
object, sparse dgCMatrix, or dense gene expression matrix for inclusion in a pipeline (Figure
4.3). Alternatively, the saveTME function can be used to write the returned data to disk for
further manipulation or use in applications outside of R (Figure 4.2b). Figure 4.3 shows how
saveTME can be used to save data for analysis in Python. In order to maintain consistency, the
returned value is always a list of results, whether or not multiple datasets match the query.

(a)

(b)

Figure 4.2: An overview of the main functions of TMExplorer. (a) queryTME allows users
to search and return datasets in either a descriptive table or as a list of SingleCellExperiment
objects for analysis. (b) saveTME allows users to write datasets to disk. For each dataset
written to disk, up to three files are created; a table storing the expression data as either a CSV
or matrix market file, depending on whether a dense or sparse matrix is passed to the function;
a table containing the cells and their truth label, if available; and a table containing the cell type
signature gene sets, if available.
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queryTME(has_truth = T,
has_signature = T)

For R-based
algorithms

Returned list of matching
SingleCellExperiment objects

For Python-based
algorithms

Expression <- counts(dataset)
Truth <- as.data.frame(colData(dataset))
Signatures <- metadata(dataset)$signatures

Expression = pd.read_csv(expression.csv)
Truth = pd.read_csv(cell_types.csv)
Signatures <- pd.read_csv(gene_signatures.csv)

Analysis &
Results

Analysis &
Results

Figure 4.3: An example workflow of using TMExplorer to obtain datasets for the downstream
analysis using Python and R. Users start by using queryTME to return all datasets that have
cell type labels and cell type signature gene sets, which will get a list of matching datasets
contained in SingleCellExperiment objects. Then, for R based algorithms, users can pass the
SingleCellExperiments directly if that is supported, or users can pass the individual components required. For Python based algorithms, saveTME can be used to save the files for each
dataset to disk, which can then be opened in Python for analysis.

4.3.2

TMExplorer database contents

TMExplorer is a curated collection of TME scRNA-seq datasets that have been made available
as an R-package. I created TMExplorer to improve accessibility and sharing of tumour scRNAseq data. It acts as a single-entry point to various tumour scRNA-seq datasets for users interested in studying gene expression of the TME at the single-cell level. Currently, the collection
contains 27 datasets, including 23 datasets derived from human tumours and 4 datasets derived
from mouse tumours. This comprises 16 different cancer types including leukaemia [37, 88],
breast [9,21,47,93], colorectal [53], glioblastoma [23,66,95], glioma [28], head and neck [69],
astrocytoma [89], oligodendroglioma [87], melanoma [24, 45, 85], lung carcinoma [51], pancreatic [55, 68, 84], and prostate [60]. Numbers of cells and genes vary across datasets and
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fall within the range of 5,796-57,915 genes and 74-57,530 cells. Each dataset is provided as
processed gene expression data. I did not include raw scRNA-seq data (i.e. FASTQ files) in
our collection because these files tend to be very large and can be accessed through the SRA,
if available. Out of the 27 datasets, cell-type annotations are also provided for 14 datasets and
gene signature information is provided for 10 datasets, so that users may access and use this
information in their analyses. Users can browse through the available datasets using the metadata table and then choose which dataset(s) they would like to analyze. Users can also save the
datasets for use outside of R, for instance in Python or web-based analysis pipelines.

4.3.3

TMExplorer search capability

An important feature of TMExplorer is that it acts as both a database and search tool that
can be easily implemented in one’s own workflow. Some other currently available scRNAseq databases have a search function, but cannot be easily integrated into workflows because
they are web-based [17, 31, 63, 65]. Currently available R-based scRNA-seq databases lack
built in search tools, requiring users to access vignettes to see the available data before it can
be retrieved for use in a pipeline [71]. TMExplorer provides a search tool that allows users to
search for datasets that fit their needs by tumour type, sequencing technology, source organism,
and more (Table 4.1), all from the R command line. This makes TMExplorer an improvement
over both R-based and web-based databases because users are able to browse and query data
from the same console they are using for analysis. By including a search tool and database in a
single package, TMExplorer provides a single point of entry to include TME scRNA-seq data
into data analysis pipelines.
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Case studies

In this section, I bring two example applications where TMExplorer can be used to facilitate
data analysis. In the case study 1, I show how TMExplorer can be combined with automated
cell-type identification algorithms to identify different cell types in TME scRNA-seq data.
Here, I also show how users can return datasets with both the signature gene sets and gold
standard annotations needed for testing cell-type identification. In case study 2, we show how
TMExplorer can be integrated with the algorithms for inferencing copy-number variations in
individual cells and facilitate the separation of malignant and non-malignant cells in multiple
tumour scRNA-seq datasets of the same cancer type.

Identifying different cell types in TME scRNA-seq data

Often, when using TME scRNA-seq data, we are interested in the cellular composition of the
dataset. In order to find this, automated cell type identification algorithms are used. This is
usually done by first clustering the cells, and then assigning appropriate cell type labels to each
cluster [26]. In Figure 4.4, I show how TMExplorer can be combined with a clustering method
(e.g. Seurat [80]) and a cluster labelling method (e.g. GSVA [41]) to create a workflow for the
identification of cell populations within a dataset. Seurat requires only the gene expression matrix to perform clustering, but GSVA requires a list of cell-type signature gene sets in addition
to the expression matrix. TMExplorer can return all of the datasets that have signature gene sets
available using queryTME(has signatures = TRUE). If after identifying the cell types within a
dataset, users want to assess the performance of their workflow by comparing the automated
annotations to those reported alongside the dataset, the has truth = TRUE parameter can be
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added to queryTME to only return datasets that have gold standard labels available. Seurat and
GSVA can be replaced by any other tool that accepts a SingleCellExperiment object or a matrix
of gene expression values, providing flexibility for users to incorporate TMExplorer into their
own workflows.
TMExplorer

queryTME(has_truth = T,
has_signature = T)
Seurat
Clustering

List of datasets

Gene
Expressions

Gene
Signatures

GSVA Cluster
Labelling

Cell Type
Annotations

Evaluating Labelling
Results

Results

Figure 4.4: A case study on using TMExplorer to identify cell types. A case study showing
how TMExplorer can be used in order to obtain datasets for cell cluster labelling via Seurat
and GSVA. queryTME can be used to return those datasets which have both gene signatures
and cell type annotations required for testing the automated identification of cell types. The
expression data can be passed to Seurat for cell clustering, and the gene signatures can be used
by GSVA to identify the cell types in Seurat’s clusters. Finally, the cell type annotations can be
used as the truth labels to measure the performance of the results obtained by Seurat clustering
followed by GSVA.

Inferencing copy number variations in multiple datasets of the same cancer type
Single cell sequencing is an important tool that enables the dissection of TMEs into malignant
and non-malignant cells. Researchers interested in comparing the tumour composition across
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different datasets of a specific cancer type would have to collect datasets from different sources
prior to application of separation methods. With TMExplorer, users can easily access multiple
datasets of a specific tumour type, as well as the accompanying cell type annotations and/or
gene signature information from one location, thus avoiding inconsistencies when acquiring
data from different databases. TMExplorer can be easily incorporated with other packages into
workflows for the analysis of scRNA-seq data, therefore enabling users to access and use the
data entirely within R.
Figure 4.5 displays an example workflow that uses queryTME(tumour type = “Glioblastoma”) to retrieve datasets of a specific cancer type (i.e. glioblastoma) for use in the downstream analysis. In this example, we retrieved glioblastoma datasets from the TMExplorer
database as SingleCellExperiment objects and converted them to gene expression count data
matrices. We then applied a copy number variation (CNV) inferencing method called CONICSmat [62] to each of the datasets individually, and generated heatmaps displaying the inferred
CNV patterns. This allowed us to separate malignant and non-malignant cells considering
their long-range CNV patterns. The proportion of malignant and non-malignant cells and the
patterns of CNV across the different datasets can then be compared.

4.4

Discussion

The emergence of single-cell RNA sequencing has enabled the study of tumour composition
and phenotype. With the increasing use of scRNA-seq in cancer research, scRNA-seq data
from TMEs continues to be generated and published. In order to streamline the data collection
process for researchers interested in studying the TME, I created a curated database of TME
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scRNA-seq datasets, made available as an R-package called TMExplorer. Here I have built a
database using a variety of cancers from multiple sources. We searched NCBI [27,29] for TME
scRNA-seq datasets that contain gene expression data, as well as comprehensive metadata such
as tumour type, sequencing technology, cell type annotations, and gene signatures. In total, 27
datasets representing 16 different cancers are represented, along with their cell type annotations
and cell type signature gene sets if they were available.
TMExplorer addresses a gap in currently available scRNA-seq databases by providing a
focused, easily accessible database as an R package. TMExplorer has several advantages over
other currently available scRNA-seq databases, the most prominent being:
1. Existing curated scRNA-seq databases consist of mostly normal tissue or non-cancer data
and relatively few cancer datasets. To allow researchers to easily locate and access TME
scRNA-seq data, we curated publicly available TME datasets and made them available
in a database accessible as an R package. With TMExplorer, researchers can access all
publicly available TME scRNA-seq datasets from a single location and can also return
multiple datasets that match their desired criteria with a single command.
2. TMExplorer provides a variety of search parameters (Table 4.1) that can be used to return
a subset of the available data that matches specific criteria. The parameters were designed
so that users can search for matching datasets without having to first view a list of all
available datasets, making it easier and faster to access data of interest.
3. The majority of existing scRNA-seq databases can only be accessed online as web-based
tools and are not easily incorporated into pipelines for analysis of scRNA-seq data. Since
many researchers use R or Python for their analyses, I chose to provide TMExplorer as
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an R-package so that it may be easily integrated into existing pipelines.
4. Some analyses require more than just gene expression information, and TMExplorer
provides cell type annotations and cell type signature gene sets alongside gene expression
matrices, where they are available. This facilitates the use of a wider range of analysis
methods without requiring additional work from the researchers.
We regularly maintain TMExplorer and add new datasets to our database as they get published.
Additionally, we have provided an issue template and vignette on GitHub showing how users
can process their data and submit it for inclusion in the package. Users who have found new
published datasets or sequenced their own should read the formatting instructions and open a
new issue using our template. The users who want their dataset to be included in TMExplorer
need to provide a description of the dataset, a link to the source for the dataset, a link to the
dataset files that will be added to the package, and the completed metadata table. TMExplorer
is generalisable to many other sources, single-cell or not, and has already been forked for
scATAC-seq data in scATAC.Explorer [35].
In summary, TMExplorer allows researchers to easily access, share and integrate TME
scRNA-seq data into their own analysis pipelines. TMExplorer can be used to access data
needed for the validation of new algorithms and to allow researchers interested in the tumour
micro-environment to study specific types of cancer.

4.5

Software and data availability

All included datasets are from free, public sources [27, 29] and all source code is freely available on Github (https://github.com/shooshtarilab/TMExplorer). Data is hosted on
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figshare [78] at the following link:
https://figshare.com/projects/TMExplorer_A_Tumour_
Microenvironment_Single-cell_RNAseq_Database_and_Search_Tool/
101471.
Users wishing to have their data added to TMExplorer can open an issue at the following
link with a link to their study and data along with a brief description and we will review it for
inclusion.

https://github.com/shooshtarilab/TMExplorer/issues.

TMExplorer is also available as an R BioConductor package at the following link:
https://bioconductor.org/packages/release/data/experiment/html/
TMExplorer.html
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Figure 4.5: A case study on using TMExplorer for inferring CNVs. A case study showing
how TMExplorer can be used to obtain multiple datasets for a specific tumour type, to be used
with CNV-based separation methods, such as CONICSmat. QueryTME returns datasets of a
specific tumour type, such as Glioblastoma. These datasets can then be inputted directly into
large-scale CNV inferencing methods, such as CONICSmat.

Chapter 5
Applying the Framework to Automated
Cell-type Labelling Methods

5.1

Introduction

Single cell RNA sequencing (scRNA-seq) allows researchers and clinicians to precisely define
complex cell populations by examining gene expression in thousands of individual cells per
analysis. This is particularly useful in the context of cancer, as tumours and their surrounding
micro-environment can be incredibly heterogeneous, consisting of various cell types including
but not limited to malignant cells, cells of the tissue of origin, immune and endothelial cells,
and fibroblasts [40, 48, 52, 85]. Such heterogeneity often has functional effects that lead to cancer progression, metastasis and treatment resistance [4, 48, 59], emphasizing the importance of
correctly describing the cell types present in a given tumour. Recently, scRNA-seq technologies have been successfully used to elucidate tumour composition and identify specific cell
types that negatively impact treatment response or that may be viable for immunotherapeutic
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targeting [72,74,85]. Use of scRNA-seq can thus provide critical insight into patient prognosis
and guide the development of treatment options, driving the recent increase in implementation
of such technologies in cancer research.
While most components of standard scRNA-seq pipelines are automated, cell type labelling requires researchers to manually examine the expression of marker genes in their data
in order to annotate cell types. This often involves literature searches instead of standardized gene profile ontologies, is time-consuming, and can result in inconsistent nomenclature
or labelling practices, making reproducibility and comparison across studies a challenge. To
address these problems, several automated cluster labelling algorithms have been recently developed, typically implementing either unsupervised, cluster-based methods, or supervised,
cell-based methods [1, 76].
To assign labels to clusters, cluster-based methods first group cells based on their gene expression profiles, then assign cell type labels to each of these groups, or clusters. To do this,
they make comparisons between the scRNA-seq dataset of interest and reference gene expression signatures, which are typically composed of marker gene sets compiled from literature
searches or continuous marker gene expression values from experimental techniques such as
microarrays or RNAseq [41, 64]. While these methods perform well, they are limited by their
reliance on marker gene data, which is often not available for tissues of interest [26].
In contrast, supervised cell-based labelling approaches rely on training using annotated
training datasets containing the same cell populations as the query data. Such algorithms make
the assumption that gene expression patterns are discriminative between cell types, as this
has been demonstrated in experiments using healthy tissue data [1]. Cell-based algorithms
thus learn the distribution of each cell type from the training dataset by training supervised
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models which are then used to predict cell identities. If a query dataset, however, contains
cell types not present in the reference data, cell-based algorithms cannot predict the identities
of the corresponding cells. The accuracy of such methods may also vary with particularly
heterogeneous cell groups [76], and computational times can be high [1].
Cancer data poses a unique challenge in the field of scRNA-seq, as tumour micro-environments
are extremely complex. Some methods do have functions created with cancer cells in mind
[25], however most labelling tools were developed either outside of cancer contexts or for
specific cell or tissue types, making it difficult to evaluate how well they may perform with
highly diverse cancer datasets. Indeed, performance of scRNA-seq cluster labelling algorithms
has been shown to decrease as the complexity and number of cell populations in a dataset
increase [1]. With respect to cell-based algorithms, while gene expression patterns may be discriminative between healthy cell types the same may not be necessarily true for tumours and
their micro-environment [70]. This suggests that particular care must be taken when selecting
an appropriate method for the labelling of cancer scRNA-seq data, as stem cell differentiation,
accumulation of mutations and selective pressures from the tumour micro-environment can
all drive tumour heterogeneity, increasing the number and complexity of cell subpopulations
present in a given tumour sample. While comparisons between scRNA-seq cluster labelling algorithms have been previously made [1,26] these evaluations focused on normal tissue samples
and how well these tools might perform with more complex tissues such as tumours remains
unclear.
I therefore present an assessment of 26 scRNA-seq cell type labelling algorithms to determine their performance in the specific context of cancer datasets. Nineteen of the algorithms
are cell-based, requiring training datasets, while the remaining 7 are cluster-based, and require
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marker gene sets. The performance of each algorithm was determined using 8 cancer datasets,
including brain, breast, lung, colorectal, leukaemia, melanoma and pancreatic cancers. For
cell-based methods, 5-fold cross-validation was used to evaluate the ability of a method to
predict cell type identities and for cluster-based algorithms, clustering the cells followed by
automated labelling was assessed. I evaluated the performance of each algorithm, taking into
account several aspects and conditions that are of particular interest when working with cancer
data. This includes assessing performance of the algorithms in detecting under-represented
cell populations or specific categories of cell types, effects of imbalanced datasets on cell type
predictions, as well as patient-based analyses. To our knowledge, this study encompasses the
largest cohort of cell type labelling algorithms assessed to date, and uses the largest cancerfocused test set to do this assessment. Our results exemplify the specific challenges associated
with labelling of tumour scRNA-seq data, and highlight which algorithms perform well in a
cancer context, helping cancer researchers and clinicians select the preferred tools for their
analyses.

5.2
5.2.1

Methods
scRNA-seq cluster labelling algorithms

For this study, I compared a total of 26 scRNA-seq cell type labelling algorithms. Of these, 19
rely on cell-based, supervised methods, including 7 general purpose algorithms not developed
specifically for use with scRNA-seq. The 7 remaining algorithms are unsupervised clusterbased methods. Our cohort represents a wide variety of approaches used for cell type labelling,
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and encompasses those developed specifically for scRNA-seq data as well as general-purpose
tools frequently implemented in scRNA-seq analyses. This allowed me to thoroughly evaluate
a broad set of strategies for scRNA-seq cluster labelling to determine which tools perform
favourably when analysing tumour samples. Names, categories, availability and descriptions
of each algorithm are provided in Table 5.1.
Table 5.1: Summary of cell type labelling algorithms used.
Name
ACTINN

Category
Cell-based

Language
Python

CaSTLe

Cell-based

R

Cell BLAST

Cell-based

Python

CHETAH

Cell-based

R

KNN 9

Cell-based

Python

LAmbDA

Cell-based

Python

LDA

Cell-based

Python

LDA+rej
NMC

Cell-based
Cell-based

Python
Python

RF

Cell-based

Python

scID

Cell-based

R

scmap-cell
scmap-cluster

Cell-based
Cell-based

R
R

scPred

Cell-based

R

scANVI

Cell-based

Python

SingleCellNet

Cell-based

R

Brief description
Neural network-based with 3 hidden
layers
XGBoost classification model with
random forest classifier
Modified neural network-based
classifier; cell-to-cell similarity
Hierarchical classification based on
similarity to reference dataset
General purpose k-nearest
neighbour-based classifier, with k=9
1-layer neural network-based with
bagging
General purpose classifier using
linear discriminant analysis
LDA with rejection option
General purpose classifier using
nearest mean classification
General purpose classifier using
random forest method
Framework based on Fisher’s linear
discriminant analysis
k-nearest neighbour-based classifier
Classifier based on distance between
a cell and the nearest cluster centroid
Support vector machine
(SVM)-based classifier; combines
dimension reduction with machine
learning for classification
Deep generative model with
Variational Inference
Random forest-based classifier
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SingleR

Cell-based

R

SVM

Cell-based

Python

SVM+rej
adobo

Cell-based
Cluster-based

Python
Python

CIBERSORT

Cluster-based

R and Java

GSEA

Cluster-based

Java

GSVA

Cluster-based

R

MetaNeighbor Cluster-based

R

5.2.2

ORA

Cluster-based

R

scCATCH

Cluster-based

R

Classifier based on correlation
between reference and test data
General purpose classifier using a
support vector machine method with
linear kernel
SVM with rejection option
Cluster labelling based on weighted
marker gene expression and cell type
activity scores
Linear support vector
regression-based labelling
Determines gene expression patterns
using weighted enrichment scores
Determines gene expression patterns
using discrete Poisson kernel-based
enrichment scores
Cell type labelling based on
neighbour voting
Cell type labelling based on
over-representation of given gene sets
Cell type labelling with
evidence-based scoring protocol

Datasets

While many of the algorithms I selected were previously considered in one of two studies
comparing various scRNA-seq labelling methods, neither of these studies focused on cancer
datasets specifically, and instead primarily used normal tissue samples [1, 26]. Therefore, to
evaluate how accurately these tools are able to label complex tumour data, I used 8 datasets
from various cancer tissues. The datasets were obtained from either Gene Expression Omnibus
(GEO), ArrayExpress (AE), or Genome Sequence Archive (GSA).

Breast cancer.

Single cells from 11 human primary breast cancer tumours of 4 different

subtypes comprise this dataset, including cancer cells, stromal cells, and immune cells from
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the tumour micro-environment [21]. This data is available on the GEO portal under GSE75688.

Colorectal cancer.

This dataset represents single cells isolated from 11 human primary col-

orectal cancer tumours at varying stages [53]. Cell types include T cells, B cells, macrophages,
fibroblasts, mast cells, epithelial cells, and malignant cells from the tumour micro-environment.
This data is available on the GEO portal under GSE81861.

Glioblastoma. This dataset details the gene expression profiles of single cells isolated from 4
primary glioblastoma patients [23]. It consists of cells from the tumour core and peritumoural
space of each patient, and samples are composed of malignant cells, vascular cells, immune
cells, neuronal cells, and glial cells. This data is available on the GEO portal under GSE84465.

Melanoma.

This dataset contains gene expression profiles for single cells isolated from 33

human melanoma tumours, 17 of which were newly collected from patients and 16 of which
were from previously reported tumours [45]. Cell types include malignant cells, stromal cells,
and immune cells that compose the melanoma tumour micro-environment. This data is available on the GEO portal under GSE115978.

Metastatic melanoma. This dataset consists of single-cell expression profiles for cells isolated from 19 human melanoma tumours [85]. It includes malignant, immune, and stromal
cells taken from ten metastases to lymphoid tissues, five metastases to subcutaneous or intramuscular tissue, three metastases to the gastrointestinal tract, and one primary acral melanoma.
This data is available on the GEO portal under GSE72056.
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Lung. For this dataset, single-cell expression profiles were generated for cells isolated from
5 patients with untreated, non-metastatic lung squamous carcinoma or lung adenocarcinoma
[51]. Cells were isolated from both tumour and normal lung tissue, and cell types present
include cancer cells, immune cells, fibroblasts, endothelial cells, alveolar cells, and epithelial
cells. This data is available on the ArrayExpress portal under E-MTAB-6149, E-MTAB-6653.

Pancreatic. This dataset consists of pancreatic cells isolated from 24 primary pancreatic ductal adenocarcinoma tumours and 11 control pancreases [68]. It comprises various subgroups of
malignant and stromal cell types. This data is available on the GSA portal under CRA001160.

Acute myeloid leukemia (AML). This dataset is composed of cells from bone marrow aspirates from 16 AML patients and 5 healthy donors [88]. Cell types include haematopoietic stem
cells, as well as populations of erythroid, lymphoid, and myeloid cell types. This dataset only
includes gene signatures for some of the total cells published, and any cell type without gene
signatures available was removed for our study. This data is available on the GEO portal under
GSE116256.

5.2.3

Data pre-processing

I performed the following steps prior to the running of all cell type labelling algorithms: (i)
collection of count data; (ii) removing cells with unknown truth labels; and (iii) normalization
of counts. While data preprocessing specifics are unique to each method, I first collected raw
count data from the TMExplorer database, which contains more than 21 scRNA-seq datasets
from tumour micro-environments [20]. I selected these 8 datasets from the database based on

68

Chapter 5. Applying the Framework to Automated Cell-type Labelling Methods

cell type label availability, which is necessary for evaluation of the performance of the cluster
labelling algorithms. Seven out of the 8 datasets have raw count data, while the Breast dataset
only has TPM data. We downloaded the raw sequencing data for the breast cancer dataset,
aligned it to the human genome (hg38) using the Galaxy pipeline, and obtained the count
data [2].

5.2.4

Cell type prediction

Cell-based algorithms take a matrix of individual cells’ gene expressions as input and return a
prediction for each cell using supervised learning methods. Cluster-based methods first require
cells to be grouped into clusters, then take the average gene expression in those clusters as
input.
For cell-based methods with built-in normalization techniques, count data was directly provided to the algorithms. For general purpose algorithms from the scikit-learn package [67] not
developed specifically for scRNAseq data (Table 5.1), we calculated log10(count+1) values for
the gene x cell matrices of every dataset. We used 5-fold cross-validation to predict cell type
labels. More specifically, each dataset was divided into 5 folds, with a stratified strategy such
that each fold contains equal proportions of each cell type. we then used the same training and
testing folds for all the methods. For general purpose algorithms with a rejection function, 0.7
was used as the threshold so that predictions with lower confidence were rejected and marked
as “Unlabelled”. For other algorithms with a built-in rejection step, their default parameters
were used to reject unconfident predictions.
For cluster-based methods, raw count data was loaded into the Seurat v3.2 pipeline and nor-
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malised using Seurat’s LogNormalise method, after which we applied Seurat Louvain clustering with default parameters [80]. After clustering, I used Seurat’s output partitions to compute
the average expression per cluster for cluster-labelling algorithms. For algorithms with built-in
normalisation techniques, I provided an average of raw count expression per cluster, and for
algorithms without built-in normalisation I normalised the raw counts using full quantile normalisation prior to computing average expression per cluster. These average expressions per
cluster are provided to cluster-based labelling algorithms (i.e. GSVA, GSEA, ORA, Adobo,
scCATCH, CIBERSORT, MetaNeighbor) to obtain a set of predicted labels. These methods
obtain predictions by comparing differentially expressed genes within each cluster to a list of
genes that are known to be strongly expressed by certain cell types. GSVA, GSEA, ORA,
CIBERSORT, and MetaNeighbor take a list of cell type signature gene sets as input, while
Adobo and scCATCH use their own built-in databases.

5.2.5

Ranking cell type labelling algorithms

To evaluate and compare the ability of each algorithm to identify specific cells within the 8
datasets, I used F1 scores. To calculate F1 scores, I first computed the score for each individual
cell type according to equation 2.7.
Since this is a multi-class problem, I cannot represent the performance of each algorithm on
a dataset as a single score using the above formula. To obtain a single score for each algorithm
on a specific dataset I used weighted-averaging, as in equation 2.19.
In order to obtain a 95% confidence interval for the F1 scores, I used bootstrapping. Ten
thousand re-sampled prediction sets were generated from a labelling algorithm output using
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subsampling with replacement, and an F1 score was calculated for each prediction set. The
50th percentile of these F1 scores represents the median F1 Score used for comparison, and
the 2.5th and 97.5th percentiles determine a 95% confidence interval for an algorithm’s performance on a dataset (Figure A.1).
In addition to the F1 score, I also explored 4 other measures of accuracy: precision, recall,
adjusted Rand index (ARI), and homogeneity (Figure 5.1). To explore their degree of mutual
redundancy, I first assembled a set of labelling partitions generated by different algorithms on
different datasets. For each labelling partition, its 5 accuracy measures were computed and a
principal component analysis was then performed on the set of partitions. All measures were
highly correlated among each other as well as with the first principal component PC1, whereas
the other principal components were correlated to a much lower extent with the 5 measures
(Figure 5.2). The analysis was done separately for cell-based and cluster-based algorithms
and returned similar results. This suggested that the F1 score was an adequate representation
of the group of quality measures that I examined, hence I used the F1 scores in subsequent
calculations.

5.2.6

Cell type & cell category specific analysis

To compare performance of each algorithm on various cell types, I collected the F1 scores for
all cell types in each dataset and compared them across algorithms (Figure A.2). I also evaluated the performance across various cell type categories to assess whether certain algorithms
are better at detecting certain cell categories. For this, individual cell types in each dataset were
first grouped into broader categories using the Cell Ontology (https://www.ebi.ac.uk/ols/ontologies/cl)
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(a)

(b)

(c)

(d)

Figure 5.1: Heatmaps of additional performance measures we tested. All measures were found
to correlate with F1 Score. In each figure, the x-axis shows various datasets and the y-axis
shows the different algorithms. Algorithms in black are cell-based, those in red are clusterbased. (a) shows the adjusted Rand index (ARI), (b) shows the homogeneity, (c) the precision,
and (d) the recall.
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Figure 5.2: Correlation between various metrics tested for assessing performance of cell type
labelling methods. Each cell represents a correlation between two different metrics or principal
components and the panels show that all metrics are correlated with F1 score

[11]. Each category is composed of similar cell types based on their ontological relationships;
for example, T-cells, B-cells and other immunological cell types would all be categorized as
Immune cells.

For a given category, a median score was calculated using the per-class F1 score of each
cell type within that category. Specifically, I first generated an F1 score for each possible
combination of algorithm/dataset/cell type. Using this, I then calculated the median score
of all cell types within a given category for each dataset to create F1 scores for each possible
algorithm/dataset/category combination. I further compared the performances of all algorithms
on labelling cell types designated as malignant (tumour) and those designated as non-malignant
(non-tumour) using a Wilcoxon rank-sums test.
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Patient-based analysis

To compare each cell-based algorithm’s ability to correctly identify the potentially different
cells in a new patient, I gathered data identifying which cells in each dataset belong to which
patient. For this analysis, I included Melanoma, Metastatic Melanoma, Lung, Pancreatic, and
AML datasets, which had patient information available. We then separated the 5 datasets into
5-fold training and testing sets, making sure that each test set was composed of unique groups
of patients. Using these new test sets, we re-trained, predicted the cell types, and scored all 19
cell-based algorithms. This more closely simulates a real-world scenario where a lab may use
a pre-trained classifier to identify the cells present in new patients.

5.2.8

Analysis of performance on imbalanced datasets

I examined the performance of algorithms on imbalanced data, in which some cell types may
contain many more samples than other cell types within the same dataset. We first generated
synthetically balanced data by subsampling each dataset for 50, 100, 200, 400, or 800 cells per
cell type present, then assessed changes in the performance of these algorithms when applied
to synthetically “balanced” data compared to the original “imbalanced” data. As the Breast
and Colorectal datasets are particularly small (564 and 376 total cells, respectively), I did not
include them in this analysis. Thus, using 5 subsample sizes on 6 datasets provided us with 30
“balanced” subsampled datasets. Cell-based algorithms were then trained and tested using the
“balanced” data. Using F1 scores as a metric, I observed the performances of each algorithm
across the 30 subsampled datasets. I compared the F1 scores of our synthetically balanced
datasets against those of the original datasets, and implemented hierarchical clustering to group
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the algorithms based on their overall stability. Algorithms that are not determined to be part of
the large cluster of algorithms with small changes in F1 score are considered unstable.

5.2.9

Under-represented cell type detection analysis

To evaluate the ability of each algorithm to identify specific cell types that represent a small
portion of a dataset, I selected all cell types containing fewer than 1000 and comprising less
than 30% of a dataset, and cell types comprising less than 5% of a dataset. I then assessed how
the algorithms perform at detecting under-represented cell populations.

5.3

Results

In this study, I examined the performance of 26 scRNAseq cluster labelling algorithms using 8
scRNAseq cancer datasets in what is, to our knowledge, the largest such benchmarking study.
Our datasets span a variety of cancer types and are of varying sizes with respect to number of
cells, genes and cell types, and were obtained using varying sequencing technologies (Figure
5.3). For all of these datasets, I obtained the truth labels from the original paper published
the dataset. Figure 5.3c depicts tSNE plot coloured by the truth labels for each dataset. Of
the 26 algorithms used, 7 use cluster-based approaches, while 19 are cell-based. I also take
into consideration several types of analyses and experimental conditions that are particularly
relevant in cancer research and clinical application to provide the most thorough evaluation
of labelling methods in a cancer context. This includes the detection of under-represented
cell populations in specific datasets, correct labelling of cells from individual patients, and the
effects of imbalanced data on labelling accuracy.
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(b)

(c)

Figure 5.3: The 8 selected cancer datasets provide a wide range of cell, gene and cell type
numbers. (a) Eight cancer datasets from a variety of human tissues, generated using multiple
sequencing technologies, were used in this study. (b) All numbers shown are after preprocessing has been done, and represent the size of the datasets given as input to all algorithms. (c)
tSNE plot of each dataset coloured by truth labels.
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5.3.1

Overall performance and running time of all algorithms

I began by comparing the performance of each algorithm across all datasets, using F1 score as
a performance metric. For each algorithm, I calculated F1 scores per individual dataset, as well
as median F1 score across all datasets to indicate overall performance (Figure 5.4). Although
some cluster-based algorithms performed well on specific datasets, median F1 scores indicate
that cell-based algorithms outperform cluster-based algorithms in general. Overall, 11 cellbased algorithms showed an average F1 score of 0.9 or higher. The top performers were scPred,
with an F1 score of 0.97, followed by CaSTLe, scANVI, and SVM, with F1 scores of 0.96.
In contrast, the most successful cluster-based algorithms were ORA, GSVA and CIBERSORT,
with average F1 scores of 0.56, 0.51 and 0.48, respectively. I repeated this analysis using
ARI, homogeneity, precision, and recall as performance metrics, and observed similar trends
(Figures 5.1, 5.2).
To evaluate the speed and scalability of the 26 algorithms, we recorded and analysed the
running time of each algorithm on each of the 8 cancer datasets. Our calculations of the running time for cell-based algorithms consisted of training time and predicting (testing) time
used in the cross-validation, while the running time of cluster-based algorithms consisted of
time used for clustering and labelling. Figure 5.4 shows the results of the overall running
time in ln(second + 1), with algorithms ordered based on their median F1 scores across the
8 datasets. Figure 5.5 shows the training and testing or clustering and cluster labelling time
for cell-based and cluster-based algorithms on all datasets, respectively. It should be noted
that some cell-based algorithms implement training and predicting in a single function in their
original published packages, thus we could only record the total running time for those meth-
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Figure 5.4: Performance and running time summary of cell type prediction methods across 8
cancer datasets. (a) F1-scores of 19 cell-based methods (Y-axis, black labels) and 7 clusterbased methods (Y-axis, red labels) on 8 cancer datasets (X-axis). Datasets are sorted from
fewest to most cells, and algorithms are sorted along the Y-axis according to their median F1
score across all datasets. For cluster-based algorithms, Seurat was used for clustering prior
to labelling. Values are the median of a bootstrapped 95% confidence interval generated by
sampling the predictions 10,000 times. Gray squares are those where the algorithm was unable
to obtain a prediction due to scalability issues related to large sample sizes. Cell-based algorithms outperformed cluster-based algorithms, likely due to a lack of available gene signature
data - particularly for malignant cells - that cluster-based algorithms rely on for accurate labelling. (b) Running time was calculated as ln(second+1) for each dataset, and the algorithms
were ordered based on their median F1 score across all datasets, shown in (a). Cell-based and
cluster-based methods are again indicated using black and red labels, respectively, on the Yaxis. (c) Linear regression was performed based on the column normalized running time of the
algorithms and the corresponding number of cells, genes, and cell types in each dataset. Values
in the heatmap denote the coefficients of the learned models.

ods. Our results show that cell-based algorithms were faster than cluster-based algorithms
on smaller datasets due to the time that clustering takes. This is in part due to normalisation
and other early processing steps in the Seurat pipeline. Furthermore, most algorithms require
substantially more time for larger datasets. Of note, scPred, SingleR, CaSTLe, ACTINN, SingleCellNet, KNN 9, Cell BLAST, and scVI all have drastically longer running times (up to
200x longer) with larger datasets, such as lung and pancreatic, compared to their results with
smaller datasets such as colorectal and breast (Figure 5.4b).
As our datasets vary in terms of numbers of cells, genes and cell types, we have evaluated
the influence of these properties on running time. Specifically, for each algorithm, a linear
regression model was trained using the numbers of cells, genes and cell types as features, and
the corresponding running time (ln(second + 1)) as targets. Then, the coefficients of the learned
models were shown in Figure 5.4c. A majority of algorithms were primarily impacted by the
total number of cells in a given dataset, while some algorithms, such as Adobo, were mainly
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Figure 5.5: Detailing timing information for each algorithm on all datasets. Bars are split into
training and testing time or clustering and labelling time where possible. For algorithms that
include separate training and testing steps, those times are shown as separate colours in the bar.
For cluster based algorithms, the time required to cluster the data is shown on the bar.

impacted by the number of cell types.

5.3.2

Assessing performance of algorithms in detecting specific cell types

To further characterize the differences in performance between cell-based and cluster-based
labelling algorithms, I compared the F1 scores of the algorithms per individual cell type in
each of the 8 datasets (Figure A.2). Our results again showed overall lower performance for the
cluster-based methods compared to cell-based algorithms. Of note was a significant reduction
in F1 scores on malignant cell types predicted by cluster based algorithms. This is likely due
to a lack of gene signatures for malignant cell types, which are required by most cluster-based
prediction methods.
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5.3.3

Cell type and category analysis

Accounting for all 8 datasets, we identified 10 cell categories including malignant, immune,
fibroblast, endothelial, epithelial, secretory, vascular, brain, stromal and stem/progenitor cells
using Cell Ontology (https://www.ebi.ac.uk/ols/ontologies/cl) (Figure 5.6). Of these, 5 categories were present in at least 2 datasets: malignant (8 datasets), immune (8 datasets), fibroblasts (5 datasets), endothelial (4 datasets) and epithelial (2 datasets). I ranked how well these
categories were labelled by the cell-based and cluster-based algorithms using the median F1
scores (see Methods and Figure 5.6a). For cell-based methods, highest performance was observed with malignant cells, followed by fibroblasts, endothelial, epithelial, and finally immune
cells (Figure 5.6b). Cluster-based methods showed the highest performance with endothelial
cells, followed by fibroblasts, immune, malignant and epithelial cells. Of note, the median
scores obtained across these 5 categories with cluster-based algorithms had a much greater
spread compared to the median scores obtained with cell-based algorithms. This may indicate
that performance varies more across different algorithms and datasets depending on the quality
of gene signatures and the prediction method.

Further analysis of algorithm performance on malignant and non-malignant cell types using
a Wilcoxon rank-sums test showed a significant difference between the cell-based and clusterbased methods (Figure 5.6d). Specifically, for cell-based methods, the highest performance
was observed for malignant cells, whereas for cluster-based methods malignant cells were
often completely unidentifiable.
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(a)

(c)
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Figure 5.6: Cell type and category analysis. (a) Ten cell categories were identified across
all 8 datasets. A cell category score for any given algorithm on a dataset is the median of
the per-class scores for that algorithm on the classes belonging to the category (i.e. the immune cell category score is the median performance on T Cells, B Cells, and other immunerelated cells). Datasets included in each category are: Malignant (all datasets), Immune (all
datasets), Fibroblast (colorectal, metastatic melanoma, melanoma, lung, pancreatic), Endothelial (metastatic melanoma, melanoma, lung, pancreatic), Epithelial (lung, pancreatic), Vascular
and Brain (glioblastoma), Stromal (breast), and Progenitor and Stem cells (AML). (b) A boxplot showing the difference between median performance of non-malignant cells and median
performance of malignant cells. Results indicate that cluster-based algorithms performed better on non-malignant cells, whereas cell-based algorithms performed better on malignant cells.
Boxplots show the F1-scores of (c) cell-based and (d) cluster-based algorithms on datasets
for the 4 most commonly seen cell type categories. Outliers in C are small cell populations
predicted by algorithms that are unable to identify under-represented cell types (Figure 5.10).
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5.3.4

Evaluation of cell-based algorithm performance

Examining the performance of supervised cell-based algorithms, I found that they were much
more successful at correctly labelling malignant cells compared to non-malignant cell types,
as indicated by a Wilcoxon rank sums test (p<0.05) (Figure 5.6d). To see if this was due to
malignant cell populations simply providing more training data, I measured, for each dataset,
the correlation between malignant cell proportion and F1 scores, as well as the correlation of
non-malignant cell proportion and F1 scores. I observed no correlation between the proportion
of malignant cells in a dataset and an algorithm’s ability to identify malignant cells (Figure
A.4).
I did however observe that the proportion of any given cell type within a dataset appears
to affect prediction scores for that cell type in a non-linear fashion. Specifically, I found that
Spearman’s correlation shows a slight correlation between proportion of cells and an algorithms
prediction score on that cell type for the Glioblastoma (rho = 0.64, p=1.27e-17) and Breast (rho
= 0.86, p=5.25e-32) datasets (Figure A.4). This may be due to higher numbers of malignant
and immune cells relative to other cells of the tissue of origin in many of the datasets, and
drove me to examine the effects on cell prediction with balanced datasets, in which each cell
type is equally represented.

5.3.5

Examining the stability of algorithm performance on imbalanced
datasets

Most scRNAseq datasets have multiple cell type populations of varying sizes, creating an imbalance in terms of cell population frequencies 5.8. To expand upon the above analysis I
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examined the stability of each labelling algorithm, or its ability to consistently identify all cell
types in a given dataset, regardless of substantial differences in the number of cells present
per each type. We first subsampled 50, 100, 200, 400, and 800 cells with replacement from
each cell type in each of our 6 largest datasets (pancreatic, lung, AML, melanoma, metastatic
melanoma and glioblastoma) to generate balanced datasets in terms of frequency of cells across
cell types. We then measured the F1 scores of cell-based algorithms with the subsampled data.
Subsampled F1 scores were compared to initial F1 scores using full-sized datasets to identify
algorithms that exhibit the largest changes in performance when more training data is available.
We found that any increase in F1 score stabilised between 400 and 800 cells, and used only the
subsampled data containing 800 cells for our results (Figure A.5). Large differences between
a specific algorithm’s F1 scores using a full dataset and its subsampled counterpart were considered to indicate a strong effect of imbalanced data on performance, suggesting algorithm
instability (Figure 5.7).
Our results showed that most algorithms see substantial changes on at most 1 dataset. Algorithms with substantial F1 score fluctuations in 5 of the 6 datasets were considered unstable, and included Cell BLAST and scID. Cell BLAST is an autoencoder-based method which
learns latent representation for cell type prediction. To reduce false positive predictions, the
algorithm trains multiple models with different starting points and predicts cell type labels with
each of them. A significance score is computed for every prediction in each model. If a prediction is not significant in a majority of the models, the corresponding result would be rejected.
If reference datasets are relatively small, models may not be trained sufficiently, potentially
resulting in insignificant – and thus rejected – predictions like what I observed with this analysis. scID learns gene signatures for each cell type from the reference dataset, and uses them

84

Chapter 5. Applying the Framework to Automated Cell-type Labelling Methods

Figure 5.7: Algorithm performance across subsamples of datasets. The heatmap shows the
mean absolute value change in F1 scores (between balanced and original data) on all cell types
for each algorithm and dataset. I then used hierarchical clustering to identify unstable algorithms for each dataset. Singletons are indicated using a red outline.
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Figure 5.8: Boxplots showing the number of cells and proportion of cells in each class. This
demonstrates the imbalance we noticed between different cell types in some datasets. The
Lung dataset, for instance, has one cell type comprising roughly 23,000 cells, about 45% of
the dataset, while most other cell types are less than 5% of the dataset.
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by a linear discriminant analysis model to predict the query cell type labels. With a smaller
reference dataset, the quality of the learned gene signatures may affect the performance of the
algorithm.

5.3.6

Performance when training and testing on separate patients

Typical 5-fold cross validation trains a classifier on a randomly selected subset of cells from all
patients. This may not reflect a real-word scenario, where the classifier will predict cell types
in a new patient with a potentially different TME cell composition from the patients used for
training. In order to simulate this scenario, we created training and testing sets composed of
entirely different patients. I found that training algorithms on one subset of patients and testing
on another led to accurate identification of cells by 14/19 cell-based algorithms; (Table 5.2).
Most algorithms see very small changes to the per-class F1 scores in a majority of datasets
(Figure 5.9b), which suggests that these algorithms can be used in clinical settings and are
suited to many cancers, but not necessarily all. kNN9, NMC, Cell BLAST, scID, and scmapcluster all see large changes in performance when training and testing on different patients and
are unlikely to perform well in a real-world scenario.
Larger changes were, however, observed with the AML dataset regardless of which algorithm was chosen. Specifically, the large negative changes were evident for AML data in all
the algorithms that are able to identify cells when training and testing on different patients for
other datasets (Figure 5.9a). The AML dataset examines stem cells across several time points
in multiple patients, which may affect an algorithm’s ability to identify cells this way.
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Figure 5.9: Boxplots showing the change in F1 score when algorithms are trained on groups
created by separating samples from entire patients instead of randomly separating cells from
all patients. (a) Change in F1 score of all classes for all algorithms in the five datasets. (b)
Change in F1 score of all classes in each dataset for all algorithms.
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5.3.7

Under-represented cell type detection

Some scRNA-seq datasets have cell types that represent only a small fraction of the complete
sample. These cell types may be hard for some algorithms to recognise due to the low amount
of reference cells available to learn from present in the training training data. To examine ability of our algorithms in detecting under-represented cell types, we first considered cell types
represented either less than 5% of a dataset or fewer than 1000 cells and less than 30% of a
dataset. I then examined the F1 scores of all algorithms on these cell types using hierarchical
clustering, which revealed three algorithm groups (Figure 5.10). scPred, SVM, and SingleR
are always able to identify under-represented cell types, CaSTLe, ACTINN, SingleCellNet,
SVMrej, LDA, LDArej, CHETAH, LAmbDA, and NMC are unable to identify only the extremely under-represented cell types present, and the remaining 14 algorithms are unable to
identify under-represented cell types as seen in Figure A.6.

5.3.8

Algorithm recommendations

I assessed the performance of all algorithms in terms of their overall F1 score, running time,
their capability in detecting under-represented cell populations, their stability in imbalanced
datasets, and their performance when trained and tested on different patient subsets. A summary of these comparisons is provided in Table 5.2. Overall, scPred and SVM are the highest
performing algorithms; both have very high F1 scores (0.97 and 0.96 respectively), are able to
identify under-represented cell types, and are reasonably fast, though SVM is 16 times faster
than scPred when considering median running time across all datasets. CaSTLe, ACTINN, and
scANVI are also very strong performers (F1 score: 0.95), however all three are at least 5 times
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Figure 5.10: A heatmap showing the F1 scores of the top 11 algorithms on under-represented
cell types in all datasets. Under-represented cell types are those that are either fewer than 1000
cells and less than 30% of the entire dataset, or those that are less than 5% of the entire dataset.
Algorithms are clustered using hierarchical clustering. As shown by the dendrogram on the
left side of the figure, there are 3 groups of algorithms in terms of their capability in detecting
under-represented cell types: those which are successful in detecting under-represented cell
types (green); those which are not successful in detecting extremely under-represented cell
types (yellow); and those which are not successful in detecting under-represented cell types
(red)
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slower than SVM, and scANVI is unable to identify under-represented cell types.
Overall, 11 algorithms had F1 scores above 0.9: ACTINN, CaSTLe, LDA, LDA+rej, RF,
scANVI, SingleCellNet, SingleR, scPred, SVM, and SVM+rej. All are cell-based. They had
the 11 highest F1 scores (Figure 5.4), providing optimal performance, and all showed stable
performance when using imbalanced datasets (Figure 5.7). Importantly, they maintained consistent performance when training and testing on separate patients, suggesting they would be
valid in a clinical setting where classifiers trained on previously sampled patients are used to
predict cell types in new patients.
It should, however, be noted that while singleR, SVM, and scPred are able to identify all
under-represented cell types, scANVI and RF are unable to identify under-represented cell
types, and 6 other algorithms within the top 11 are unable to identify the extremely underrepresented cells present. Furthermore, scANVI, SingleCellNet, and singleR had particularly
long run times with larger datasets such as the lung and pancreatic datasets.
Table 5.2: A summary of characteristics for all algorithms.
Algorithm

Median F1
Score

Median
Run time
(s)

Stable for
imbalanced data

scPred
CaSTLe

0.97
0.96

312.0
122.5

Yes
Yes

scANVI
SVM
ACTINN

0.96
0.96
0.95

1,359.5
18.5
184.5

Yes
Yes
Yes

Identifies
Identifies
undercells when
represented training
cell types
on
different
patients
Yes
Yes
Not in
Yes
extreme
cases
No
Yes
Yes
Yes
Not in
Yes
extreme
cases
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SingleCellNet

0.95

429.0

Yes

SVMrej

0.94

60

Yes

singleR
LDArej

0.94
0.91

98.5
32

Yes
Yes

LDA

0.91

33

Yes

RF
CHETAH

0.91
0.88

7.5
15.5

Yes
Yes

LAmbDA

0.85

547

Yes

kNN9
scmapcell
NMC

0.85
0.83
0.8

155
2
1.5

Yes
Yes
Yes

Cell BLAST
scID
scmapcluster
GSVA
ORA
CIBERSORT
scCATCH
GSEA
Adobo
MetaNeighbor

0.76
0.68
0.67
0.56
0.51
0.48
0.38
0.36
0.34
0.30

3228.5
153.5
<1
428.5
435
499
341
530
624.5
457

No
No
Yes
-

5.4

Not in
extreme
cases
Not in
extreme
cases
Yes
Not in
extreme
cases
Not in
extreme
cases
No
Not in
extreme
cases
Not in
extreme
cases
No
No
Not in
extreme
cases
No
No
No
No
No
No
No
No
No
No

Yes

Yes

Yes
Yes

Yes

Yes
Yes

Yes

No
Yes
No

No
No
No
-

Discussion

I present here an evaluation of 26 scRNAseq labelling algorithms using 8 scRNAseq cancer
datasets in what is, to our knowledge, the largest and most thorough cancer-specific scRNA-seq
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labelling method benchmarking study. To determine the performance of each algorithm using
varied inputs, I chose datasets with diverse features, including cell numbers spanning from 539
to over 57,000, a range of gene numbers, and as many as 17 different cell types. I evaluated the
performance of the algorithms for each dataset overall as well as within specific experimental
conditions of interest to cancer research, thus giving a more complete representation of how
well they are able to label cancer datasets.
Our work showed that cell-based algorithms largely outperformed cluster-based algorithms,
with CaSTLe, scANVI and SVM showing the best overall performance among cell-based
methods, while ORA, GSVA and CIBERSORT were the highest-performing cluster-based
methods. Of note, two of the top performing algorithms (SVM and scPred) were support
vector machine (SVM)-based methods. Cell-based methods also showed faster running times,
particularly on smaller datasets, due to normalization and additional preprocessing required by
cluster-based methods.
Cell-based algorithms also showed particularly high performance on malignant cells in cell
type and category-based analyses. For other, less abundant cell types, balanced data analyses
showed that lower scores are driven by a lack of training data. Similarly, over-representation of
certain cell types in full datasets appeared to result in higher performance. Thus, our findings
indicate that training data availability can significantly impact performance of certain algorithms identified as unstable.
It is, however, interesting to note that particularly unique cell types may require a smaller
number of cells for training data purposes. In the Lung dataset, this is seen with mast cells,
fibroblasts, and endothelial cells; algorithm performance in the original dataset is high despite
these cell types being under-represented, and no significant increase in the balanced dataset
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was observed. This may be because these cell types are different enough from other cell types
in the dataset, making them distinguishable easily by the algorithms.
Cluster-based methods showed poor labelling of malignant cells compared to cell-based
algorithms, as indicated by category-based analyses. This is likely due to a lack of high quality
reference gene signatures available for these cell subpopulations. Many cluster-based algorithms rely on reference gene signatures to accurately predict cell type labels. They did, however, perform better with non-malignant cells compared to malignant cells. They also have the
benefit of not requiring additional training data, making them the method of choice for many
users. Nonetheless, they were largely outperformed by cell-based algorithms, making the development of improved cluster-based scRNA-seq labelling algorithms desirable. It should be
noted that the number of cells in a dataset had a substantial impact on running time for both
types of algorithms, and should be taken into consideration when selecting a labelling method
or developing new algorithms.
Our study is the first to examine the ability of scRNAseq labelling algorithms to not only
identify cells within the tumour micro-environment, but also accurately predict cell types under a variety of conditions. Such in-depth evaluations are critical for fully understanding the
applicability of such algorithms to cancer data. Specifically, I show that some algorithms
can identify common cell types within a dataset, but fail to identify less common or underrepresented cell types (Figures 5.10 and 5.7). Identifying all cell subpopulations is particularly
important when working with cancer patient data, as this can guide treatment selection and
prevent treatment resistance and disease recurrence. I also show that many algorithms are able
to accurately predict cell types when trained and tested on different patients, despite potentially
drastic differences in the tumour landscape from patient to patient. This shows that supervised
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learning algorithms can eventually be used in a clinical setting to accurately characterize cell
composition within patient tumour samples.
It should be noted that most algorithms evaluated in our study have their own implementations, and learning and incorporating these methods into a normal single cell analysis pipeline
would be time-consuming. To help researchers better use the top performing algorithms and
integrate their results with other single cell analysis, we plan to implement the top performing
algorithms identified in this study into our online platform CReSCENT (CanceR Single Cell
ExpressioN Toolkit, crescent.cloud) [61]. CReSCENT is a web portal incorporating a series
of pipelines for standardized analysis of scRNA-seq data. It also includes many public cancer datasets, which could be used as reference in the cell-based labelling. Currently, we have
implemented SVM and GSVA onto CReSCENT. Other top performers identified in this study,
such as CaSTLe and scANVI, will also be implemented in the future.

Chapter 6
Conclusions and Future Work
In this thesis, I present a novel framework for better characterising and understanding the performance of multi-class classifiers. The multi-class scenario contains many performance parameters which can create pitfalls for those wishing to develop, compare, or deploy new classifiers. The use of unsupervised learning to identify patterns in performance (through clustering
of the per-class scores in 3.3.3) provides an easy way to extract new information from existing
performance metrics, allowing researchers to better identify the strengths and weaknesses of
particular classifiers. This framework addresses inadequacies present in current benchmarking techniques and provides a more robust procedure for understanding how various classifiers
perform on different datasets.
Currently, my framework exists only in python notebooks from chapter 5. In order to facilitate its use in more studies, my framework could be packaged into a set of modules that specify
input formats and automatically perform the analyses. In addition, the visualisations used by
the framework could be further improved with an element of interactivity. This framework has
such diverse applications that a set of static figures is unlikely to apply well in all datasets.
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Even in my study, I spent a lot of time tweaking the details of the plots to best display my
results. Interactivity would allow users of the framework to not only tune the figures to their
data in real time, but glean more information on the classifiers than what is available through
static plots.
In chapter 4, I developed the TMExplorer package, which provides a focused and easily accessible collection of tumour micro-environment scRNA-seq datasets unlike any seen
before. It allows researchers to easily locate datasets where previously an extensive literature search through databases of primarily non-cancer datasets or scattered publications was
required. Through the queryTME function users can easily retrieve collections of datasets
matching their specific needs, be it a certain type of cancer, organism, sequencing technology, or more. These datasets are immediately available on the R command line, requiring
far less work before they can be used in analysis pipelines. The package is structured in a
way that allows new datasets to be continually added, and many new publications have already been added since initial release. In addition to the database itself, TMExplorer acts as a
framework for collecting additional types of data. In collaboration with my colleague Arrian
Gibson-Khademi, we have already created a fork of TMExplorer known as scATAC.explorer, a
single-cell ATAC-seq database and search tool [35]. TMExplorer can be applied to many more
domains where a large quantity of high quality data is needed for either training new machine
learning techniques, validating existing one, studying patterns specific to a certain problem, or
simply having easy access to several datasets in one place.
TMExplorer is built to be continually improved, and being a database should be constantly
updated. I have provided a template on GitHub for users or researchers to submit new data
they publish or find, which will allow continuous addition of new datasets. Similar to the fork
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for scATAC-seq data, TMExplorer could be forked for other current sequencing technologies
– or future technologies, provided their output data is formatted similar to current ones. The
framework could also be applied to new applications besides biology. For instance, to reuse my example of classifying galaxies from chapter 3, a similar package containing a set
where each “dataset” is instead a set of observations from a single galaxy could be useful for
development of new supervised learning techniques in that field.
My analysis of automated cell type labelling methods serves to not only demonstrate the
utility of my framework, but provides the largest comparison of these methods on the TME to
date that I am aware of. We showed that cluster-based methods are typically less performant
than cell-based algorithms overall, and especially when labelling malignant cell types. Cellbased methods are also often faster when you consider the time it takes to run a full clustering
pipeline prior to cluster labelling. By evaluating many aspects of performance for so many
algorithms, I was able to create a comprehensive set of recommendations that researchers can
use to select the best cell type labelling algorithm for their TME study.
While we were able to identify some algorithms with good performance (scPred, CaSTLe,
scANVI, SVM, ACTINN, SingleCellNet, singleR, LDA, RF), they all have caveats. These
could be running time or scalability (scPred, scANVI, SingleCellNet, SingleR all take much
longer to run than other algorithms, especially on large datasets), the need for high quality
reference data (any supervised method), or inability to identify under-represented cell types
(scANVI and RF are unable to identify under-represented cell types). Modifications to these
methods or development of new methods is needed before fully automated analysis of scRNAseq samples can be widely used as diagnostic tools.
Cell-based methods often fall flat due to the reference data requirement, especially in rarer
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cancers that may not have many sequenced datasets available. Without high quality datasets to
use for training, it is not possible to make good predictions. One potential avenue for improvement would be the creation of a pan-cancer reference set that could be used to train classifiers
before applying them to novel samples. This would require a large amount of data, and may
still not be applicable to all diseases due to the rarity of some cancers. Transfer learning, on the
other hand, may allow existing reference sets to be used with a wider variety of new samples.
Some of the current methods (LAmbDA, CaSTLe) do use transfer learning, and CaSTLe is
one of the top performing algorithms. Further improvements to these methods could allow rare
cancers to be identified using much more easily available training data from more common
cancers.
In my analysis, I noticed that cell-based methods are often unable to successfully recognise malignant cells, usually because gene signatures for them are unavailable or low quality.
Since the expression profile of a tumour can vary so much between individuals, collection or
creation of high quality malignant cell gene signatures may not be feasible. However, some
methods exist to separate malignant cells from non-malignant cells based on their copy-number
profile [34, 83]. These methods could be combined with existing cell clustering an labelling
technologies to facilitate the accurate identification of malignant cells. A pipeline which takes
as input a gene by cell matrix of scRNA-seq counts and outputs predictions for malignant versus non-malignant cells as well as sub-clusters for each of the two groups and other descriptive
information could improve the applicability of cell cluster labelling methods on various cancer
types.
By creating a framework to study multi-class classifiers and using it to study TME scRNAseq labelling methods, I have improved the understanding of our current ability to identify cells
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within the tumour micro-environment, and identified avenues for future work. This framework,
including the aggregator database, will improve the study of all similar multi-class problems in
the future.
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[51] Diether Lambrechts, Els Wauters, Bram Boeckx, Sara Aibar, David Nittner, Oliver Burton, Ayse Bassez, Herbert Decaluwé, Andreas Pircher, Kathleen Van den Eynde, Birgit Weynand, Erik Verbeken, Paul De Leyn, Adrian Liston, Johan Vansteenkiste, Peter
Carmeliet, Stein Aerts, and Bernard Thienpont. Phenotype molding of stromal cells in
the lung tumor microenvironment. Nature Medicine, 2018.
[52] Devon A. Lawson, Kai Kessenbrock, Ryan T. Davis, Nicholas Pervolarakis, and Zena
Werb. Tumour heterogeneity and metastasis at single-cell resolution. Nature Cell Biology,
20(12):1349–1360, December 2018. Number: 12 Publisher: Nature Publishing Group.
[53] Huipeng Li, Elise T Courtois, Debarka Sengupta, Yuliana Tan, Kok Hao Chen, Jolene
Jie Lin Goh, Say Li Kong, Clarinda Chua, Lim Kiat Hon, Wah Siew Tan, Mark Wong,
Paul Jongjoon Choi, Lawrence J K Wee, Axel M Hillmer, Iain Beehuat Tan, Paul Robson, and Shyam Prabhakar. Reference component analysis of single-cell transcriptomes
elucidates cellular heterogeneity in human colorectal tumors. Nature Genetics, 2017.
[54] Yuval Lieberman, Lior Rokach, and Tal Shay. CaSTLe – Classification of single cells by
transfer learning: Harnessing the power of publicly available single cell RNA sequencing
experiments to annotate new experiments. PLoS One, 13(10), October 2018.
[55] Wei Lin, Pawan Noel, Erkut H Borazanci, Jeeyun Lee, Albert Amini, In Woong Han,
Jin Seok Heo, Gayle S Jameson, Cory Fraser, Margaux Steinbach, Yanghee Woo, Yuman
Fong, Derek Cridebring, Daniel D Von Hoff, Joon Oh Park, and Haiyong Han. Single-cell
transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Genome Medicine, 12(1):80, 2020.

106

BIBLIOGRAPHY

[56] Aaron Lun, Davide Risso, and K Korthauer. Singlecellexperiment: S4 classes for single
cell data. R package version, 1(1), 2019.
[57] Feiyang Ma and Matteo Pellegrini. ACTINN: automated identification of cell types in
single cell RNA sequencing. Bioinformatics, 36(2):533–538, January 2020. Publisher:
Oxford Academic.
[58] Eddy Mayoraz and Ethem Alpaydın. Support vector machines for multi-class classification. Lecture Notes in Computer Science Engineering Applications of Bio-Inspired
Artificial Neural Networks, page 833–842, 1999.
[59] Corbin E. Meacham and Sean J. Morrison. Tumour heterogeneity and cancer cell plasticity. Nature, 501(7467):328–337, Sep 2013.
[60] David T Miyamoto, Yu Zheng, Ben S Wittner, Richard J Lee, Huili Zhu, Katherine T
Broderick, Rushil Desai, Douglas B Fox, Brian W Brannigan, Julie Trautwein, Kshitij S
Arora, Niyati Desai, Douglas M Dahl, Lecia V Sequist, Matthew R Smith, Ravi Kapur, Chin Lee Wu, Toshi Shioda, Sridhar Ramaswamy, David T Ting, Mehmet Toner,
Shyamala Maheswaran, and Daniel A Haber. Rna-seq of single prostate ctcs implicates
noncanonical wnt signaling in antiandrogen resistance. Science, 2015.
[61] Suluxan Mohanraj, J Javier Dı́az-Mejı́a, Martin D Pham, Hillary Elrick, Mia Husić,
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(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Figure A.1: Barplots of F1 scores for each algorithm on each dataset. Black bars around each
bar represent a 95% confidence interval.
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(a)

(b)

(c)

(d)
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(e)

(f)
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(g)

(h)

Figure A.2: Heatmaps of per cell type F1 scores for each dataset. Grey values are algorithms
that were unable to run on a particular dataset due to either scalability or compatibility issues.
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(a)

(b)

(c)

(d)
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(e)

(f)

(g)

(h)

Figure A.3: Heatmaps of per cell category F1 scores for each dataset. Grey values are algorithms that were unable to run on a particular dataset due to either scalability or compatibility
issues.
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(a)

(b)

Figure A.4: Scatterplots showing the relationship between proportion of cells in a cell type and
F1 score on that cell type for all datasets across algorithms and all algorithms across datasets.
Figure A.4a shows correlations for each cell-based algorithm, and Figure A.4b shows correlations for each dataset.
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Figure A.5: The change in F1 score for various cell types when subsampled to different sizes.
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Figure A.6: A heatmap showing the F1 scores of all algorithms on the rarest cell types in all
datasets. Rare cell types are those that are fewer than 1000 cells and less than 30% of the
dataset, or those that are less than 5% of the entire dataset. Algorithms are assigned the colour
green, orange, or red according to whether they identify under-represented cells, fail to identify
under-represented cells, or only fail to identify under-represented cells in extreme cases.

121

Table A.1: Summary of cancer datasets used. Summary of the datasets used to evaluate
scRNA-seq labelling algorithms. Cancer type, number of cells, genes and tumors, sequencing technology used, annotation and gene signature availability and dataset accession numbers
are provided. GEO: Gene Expression Omnibus; AE: ArrayExpress, GSA: Genome Sequence
Archive.
Dataset
Name

Cancer
type

Cells

Genes

Tumours

Breast

Primary
breast
cancer
Colorectal
cancer
Primary
glioblastoma
Melanoma

515

57,915

11

359

57,241

11

3,589

23,465

4

6,879

23,686

33

4,645

23,686

19

51,775

22,533

5

57,530

24,005

21,933

27,899

24
tumours,
11
controls
40

Colorectal
Glioblastoma

Melanoma
Metastatic
melanoma
Lung

Metastatic
melanoma
Non-small
cell lung
carcinoma

Pancreatic

Pancreatic
ductal
adenocarcinoma
Acute
myeloid
leukemia

AML

Sequencing Cell types
technolavailable?
ogy
Fluidigm
Yes
C1

Gene
signatures
available?
Yes

Fluidigm
C1
SMARTseq2

Yes

Yes

Yes

Yes

SMARTseq2
SMARTseq2
10x
Genomics

Yes

Yes

Yes

Yes

Yes

Yes

10x
Genomics

Yes

Yes

Seq-Well

Yes

Partial

Accession
number
GEO:
GSE75688
GEO:
GSE81861
GEO:
GSE84465
GEO:
GSE115978
GEO:
GSE72056
AE:
E-MTAB6149,
E-MTAB6653
GSA:
CRA001160

GEO:
GSE116256
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